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Precision medicine is the tailoring of treatment plans to individual patients based on demographic,
clinical, genetic, or other available data. This has the potential to greatly improve a patient’s clinical
outcomes and their quality of life. Medical studies often involve time-to-event outcomes. One major
challenge for analyzing time-to-event data is that some observations do not incur an event during their
window of observation. Standard precision medicine methods cannot be used with right censored data
without producing biased estimates. Thus, there is a need to develop precision medicine methods adapted
to the censored data setting. In this manuscript we propose a number of extensions of precision medicine
methods to right censored data.
Extending some precision medicine methods to right censored data would require accurate
prediction of the failure time. Traditional models for censored data may suffer from model
misspecification and are not primarily used for prediction. Flexible machine learning methods have been
extensively adopted for prediction and have received increasing interest for censored data. We develop a
failure time prediction method that uses weighted support vector regression to make full use of the
available data and improves performance in the presence of high censoring.
A common goal in precision medicine is to identify the optimal treatment plan for patients based on
their individual characteristics. We propose two individualized treatment rule estimating methods for
right censored observational data. The methods are designed for situations where there are multiple
treatments available, or the treatment values lie on a continuum. We develop and explore the theoretical
properties of an imputation approach that could be used to extend many existing methods to right
censored data.
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CHAPTER 1: INTRODUCTION
There can be considerable variation in how different patients respond to the same medical treatments.
Treatment courses that work well for certain patients may be detrimental for others. In some cases the
effectiveness of the treatments depend on observable patient characteristics. For example, when treating
hypertension it has been reported that certain classes of drugs work better for men than for women
(Zimmerman and Sullivan, 2013). The goal of precision medicine is to use observed clinical,
demographic, or genetic characteristics to identify the treatment that will work best for individual
patients.
By tailoring treatment plans to individual patients, precision medicine has the potential to greatly
improve not only a patient’s clinical outcome, but also their quality of life. If patients are given
suboptimal treatments, it can increase the probability that additional treatments will be needed.
Undergoing more treatments places patients at greater risk for adverse events, and can substantially
increase the financial burden of treatment. Additionally, when treatments involve invasive procedures,
identifying the patients for whom the potential benefits of the procedures do not outweigh the risks can
reduce unnecessary suffering.
In many medical studies, we wish to learn about the development and progression of diseases and
other conditions over time. This naturally leads to time-to-event data where the outcome is the period of
time between the initiation of follow-up and observation of the event of interest, commonly referred to as
a failure time. It may not be possible to observe the event of interest for some subjects because they are
lost to follow-up at some point during the study. This can happen for a number of reasons including
subjects being unavailable to return for clinic visits or because they withdraw their consent to be in the
study. These subjects are said to be right censored. This censoring results in a missing data problem that
can cause issues with analyses if it is not correctly accounted for. Because there is a known amount of
event-free time, the censored observations still contain information that can be used to better understand
the disease process.
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Several precision medicine methods rely on accurate estimation of certain quantities relating to a
patient’s health. Examples include regression-based estimation methods and doubly robust estimators
(Qian and Murphy, 2011; Robins et al., 1994). The most commonly used quantity for these types of
methods is the conditional mean outcome. Because we cannot follow study subjects indefinitely, the
mean outcome is rarely well defined for time to event data. Rather than base these methods on the mean
outcome, it is often possible to use the median (or some other quantile) survival time which can be
predicted using traditional methods for analyzing right censored data. However, for conditions where the
event of interest is rare, the median survival time may not be estimable from the data.
There has been recent work in using machine learning (ML) methods to predict the restricted mean
or median survival time over some predefined interval. These methods have the desirable property of
always having a well defined quantity that can be used for regression-based and doubly robust estimators,
but they do not always correctly account for the censored observations (Shivaswamy et al., 2007; Khan
and Zubek, 2008; Van Belle et al., 2010, 2011), or they do not make full use of the available information
(Goldberg and Kosorok, 2017). In Chapter 2 we develop a failure time prediction method that addresses
both concerns regarding existing methods. We use inverse probability of censoring weights (IPCW) to
correct for the bias due to censoring resulting in unbiased estimates. We also makes full use of the data
by directly incorporating information from the censored subjects. Additionally, we develop a inverse
weighting approach that can correct for the probability of observation for the censored subjects.
Being able to predict the optimal treatment rule for a patient using their specific characteristics is
one of the most important goals of precision medicine (Kosorok and Laber, 2018). Early approaches for
finding individualized treatment rules (ITRs) focused on using data from a two-arm randomized clinical
trial with fully observed outcomes (Qian and Murphy, 2011; Zhao et al., 2012). However there is
significant interest in developing ITR estimation methods for other data sources (Kallus, 2017; Zhao
et al., 2014; Wang et al., 2016; Cui et al., 2017; Liang et al., 2018). For example, when clinical trials are
not feasible, we would need methods that can correct for the selection bias and confounding that is
common in observational studies.
In Chapter 3 we develop a ITR estimation method for right censored observational data when
multiple treatment options are available. We do this by extending balanced policy evaluation and
learning (Kallus, 2017) to the right censored data setting. We develop an imputation approach that
replaces the censoring times with the conditional expected value of the failure time. This approach offers
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improvements over existing methods because it has less restrictive assumptions than regression-based
approaches, but does not suffer from high variance issues like other weight-based approaches.
In Chapter 4 we develop a dose finding method for right censored data. This approach estimates
ITRs when an infinite number of treatment lie on a continuum. We extend balanced policy evaluation
and learning as well as the imputation approach to the continuous treatment setting. As far as we are
aware, this represents the first attempt to extend ITR estimation methods to the continuous treatment
setting with right-censored observational data.
The remainder of the dissertation is organized as follows. In Chapter 2 we propose a weighted
support vector regression method for predicting right censored outcomes. A balanced policy evaluation
and learning approach to right censored data is presented in Chapter 3. We extend the balanced policy
approach to right censored data to the continuous treatment setting in Chapter 4. Chapter 5 contains
possible environmental applications of the methods developed in this dissertation. We conclude with a
brief discussion of future research directions in chapter 6. Relevant technical details for each chapter can
be found in the appendices at the end of the dissertation.
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CHAPTER 2: WEIGHTED SUPPORT VECTOR REGRESSION FOR PREDICTING CEN-
SORED OUTCOMES
2.1 Introduction
The ultimate goal of cancer studies is to provide optimal treatments and therapies for individual
cancer patients to improve their survival time or quality of life. One key component toward this goal is to
have an accurate prediction of time to the occurrence of either cancer relapse or death. However, such
time-to-event outcomes are usually subject to right censoring that precludes observation of the event of
interest, which poses significant challenges to the development of prediction methods and algorithms.
Traditional approaches to analyzing right censored data include parametric and semiparametric
models, such as the accelerated failure time, proportional hazards, proportional odds, linear
transformation, and general transformation models (Kalbfleisch and Prentice, 2011; Bennett, 1983; Zeng
and Lin, 2006). These models were not developed for the purpose of prediction. In fact, the models
provide the distribution of the failure time for a future subject, but do not directly give a predicted value
of the failure time. Furthermore, the resulting prediction based on parametric or semiparametric models
is subject to significant bias when the models are misspecified.
More recently, nonparametric methods, especially, machine learning (ML) methods, have been
developed to predict the failure time. For example, tree-based methods or random forests (Segal, 1988;
Hothorn et al., 2004; Ishwaran et al., 2008; Zhu and Kosorok, 2012) and neural networks (Biganzoli
et al., 1998; Ripley and Ripley, 2001) were proposed to predict censored outcomes. Support vector
regression (SVR) has also been extended to analyzed censored data, e.g., Shivaswamy et al. (2007) ,
Khan and Zubek (2008), and Van Belle et al. (2010). Later, (Van Belle et al., 2011) further combined
these methods into one general framework. In addition to predicting the exact failure observations
accurately, the prediction rule considered by (Van Belle et al., 2011) was also required to be compatible
with the so-called comparable pairs, the pairs of one failure and any right-censored observation for which
we know that the latter event occurs after the former one. Although computationally convenient, the
4
aforementioned ML-methods do not consider that the censoring distribution may vary from subject to
subject. This can result in selection bias for each available observation, which leads to prediction rules
that are dependent on underlying censoring distributions. Thus, the obtained prediction rule will not even
be generalizable to the same population if they experience different censoring mechanisms. This
limitation is certainly not desirable in practice. Furthermore, there have been no rigorous theoretical
results developed to justify any of these methods.
To ensure the prediction rule is independent of the underlying censoring distribution, Goldberg and
Kosorok (2017) proposed a SVR learning method using only observations with exact failure times, but
weighed them using inverse probability of censoring weighting (IPCW). They showed that when the
censoring distribution was estimated correctly, IPCW led to a Fisher-consistent prediction rule with
certain convergence rate. However, it is well known (c.f., Robins et al. (1994)) that the inverse probability
weighting method can be inefficient because it discards information from the censored subjects, so it may
result in a prediction rule with high uncertainty, especially when the censoring rate is high.
In this paper, we propose a method called weighted complete support vector regression (WCSVR)
for predicting right censored outcomes. In our method, we develop a prediction rule such that the
predicted time should be close to the exact failure time, but for right censored observations, the predicted
time should be larger than the censoring time. We apply the absolute difference to quantify the accuracy
for the exact failure times while using the hinge loss to measure the prediction consistency with the
right-censored observations. More importantly, we use a similar idea to the IPCW method to adjust for
potentially heterogeneous censoring patterns; however, for the right-censored observations, their weights
will be the inverse of the censoring density function. Theoretically, we show that the resulting prediction
rule is Fisher consistent for a convex loss for predicting failure time and is asymptotically independent of
the censoring distribution. We provide a finite sample error bound, and establish P -universal consistency
and the learning rate.
The remainder of this paper is organized as follows. In Section 2.2, we describe the proposed
weighting approach and provide a computationally efficient algorithm for implementing WCSVR. In
Section 2.3, we provide the theoretical properties of the method. Section 2.4 contains simulation studies.




In this section, we introduce our proposed WCSVR and its implementation.
2.2.1 Data and Loss Function
Let X ∈ X be a subject-level covariate vector, where X is a bounded subset of Rd. We denote the
true survival time as T̃ . Let τ denote the maximum follow-up time to account for the finite study
duration, the survival time of interest is a truncated version of the survival time, defined as
T = min{T̃ , τ}. Our goal is to obtain a prediction rule to use X to predict T . Furthermore, we let C
denote the potential censoring time and assume that C and T are independent given X .
We now describe the motivation behind our proposed loss function for estimating efficient prediction
rules for right censored data. Suppose that f(X) is a prediction rule mapping X to (−∞,∞).
Intuitively, for an uncensored subject (∆ = 1), since we know the exact failure time Y = T , we expect
f(X) to be close to T . Thus, a natural loss to quantify the prediction inaccuracy is the L1-loss,
|Y − f(X)|. For a censored subject (∆ = 0), since the only available information about T is T > Y , a
good prediction rule should output a value larger than Y . In other words, any predicted value less than Y
is known to be inaccurate. Thus, we consider using a hinge type loss, (Y − f(X))+, where
x+ = max(x, 0), so predictions incur larger losses the further they are below Y . Combining these two
situations, we consider the following loss to quantify the prediction inaccuracy:
∆|Y − f(X)|+ (1−∆)(Y − f(X))+.
Although the above loss appears to be reasonable, there are two major issues with such a choice.
First, the loss treats censored and uncensored observations equally, despite of the fact that some patients
may be more likely to be censored than others. More importantly, the average of the loss function over
the whole population depends on the censoring distribution so the prediction rule based on such a loss
function is sensitive to the censoring distribution. The latter is particularly concerning in practice, since
the learned rule from the current censored data may not be useful for future patients.
To address these challenges, it is necessary to adjust for selection bias due to the censoring
mechanism for each subject. To this end, we adopt some similar idea to IPCW in constructing the loss
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function. More specifically, we let gc(t|X) be the probability density function (with respect to some
dominating measure) for C given X and Sc(t|X) be the survival probability for C, i.e.,
Sc(t|X) = P (C > t|X). To adjust for the selection bias for censored and uncensored subjects, we
propose the following loss function










In other words, we weigh an uncensored subject by the inverse of the censoring survival probability but




























(t− f(X))2/2 dST (t|X)
= E[(T − f(X))2+]/2,
where ST (t|X) denotes the survival function for T given X . We conclude that the expectation of
LC(Y,∆, f(X)) is equal to the expectation of
LT (T, f(X)) = |T − f(X)|+
1
2
(T − f(X))2+. (2.2)
This implies that the prediction rule minimizing the risk corresponding to the constructed loss LC is
equivalent to the one minimizing a mixture of L1-loss and one-side L2-loss. As a result, this optimal rule
is expected to be independent of the underlying censoring distribution.
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2.2.2 Empirical Risk Minimization in the Reproducing Kernel Hilbert Space
Suppose that right-censored observations are available from n independent subjects and consist of
{Yi = min(Ti, Ci),∆i = I(Ti ≤ Ci), Xi}ni=1, where Ci is the censoring time for subject i, and I(·) is
the indicator function. We propose to learn the prediction rule by minimizing the empirical average of
the constructed loss (2.1) in Section 2.2.1.
Specifically, we first need to estimate the survival function of the censoring distribution, Sc(t|X),
and its density function, gc(t|X). For Sc(t|X), if the censoring time is independent of the covariates,
then the Kaplan-Meier estimator based on the observations (Yi, 1−∆i); i = 1, ..., n, can be used.
Otherwise, we consider a proportional hazards model for the censoring time by assuming its hazard rate
function to be λc(t|X) = exp{ζ ′X}λ0(t), where ζ is a vector of unknown regression parameters, and
λ0(·) is an arbitrary baseline hazard function. Then the estimate of ζ, denoted by ζ̂n, and the Breslow
(1972) estimate of the cumulative baseline hazard function, denoted by Λ̂0,n(t|X), can be used to






For gc(t|X), we adopt the kernel density estimator proposed by Diehl and Stute (1988). Specifically, let










We consider f(X) from a reproducing kernel Hilbert space associated with a kernel function
K(x, x̃), denoted byH and equipped with norm ‖ · ‖H. Then the estimated prediction rule minimizes
the following empirical risk in this space:
n∑
i=1















and λ is a tuning parameter to be selected using cross-validation.
2.2.3 Algorithm
We first consider the simple situation when f(X) is a linear function of x, i.e., K(x, x̃) = x′x̃. The
prediction function f is of the form f(X) = β′x+ b with the squared norm ‖f‖2H = β′β. Thus, we aim


















|Yi − f(Xi)|+. (2.5)





















where κ ∝ 1λ , with the constraints
∆i(β
′Xi + b− Yi + ε+ ξi) ≥ 0 ∀ i = 1, . . . , n,
∆i(Yi − β′Xi − b+ ε+ ξ∗i ) ≥ 0 ∀ i = 1, . . . , n,
(1−∆i)(β′Xi + b− Yi + ε+ χi) ≥ 0 ∀ i = 1, . . . , n,
ξi ≥ 0, ξ∗i ≥ 0, χi ≥ 0 ∀ i = 1, . . . , n.

















αi∆i(Yi − ε) +
n∑
i=1







0 ≤ αi, α∗i ≤
κ∆i
Ŝc(Yi|Xi)




which can be solved using quadratic optimization. More details about the dual form of the optimization
are provided in Appendix A.
Equation (2.7) is maximized using the quadratic optimization solver in the MOSEK library
(MOSEK ApS, 2018). The intercept parameter b does not appear in the dual form of the
optimization problem in equation (2.7), so it is found after optimization of β using a simple
one-dimensional optimization. We denote the final prediction function as f̂λ. Then the prediction of a




[∆i(α̂i − α̂∗i ) + (1−∆i)γ̂i]K(Xi, X̃) + b̂.
As a remark, since T is between 0 and τ , we can modify our prediction function as max(0,min(τ, f̂λ)).
Furthermore, to allow a nonlinear prediction function, we can adopt the kernel trick in the standard SVM
by using a nonlinear linear function, for instance, the Gaussian kernel with bandwidth σ−1/2, for
K(x, x̃) in the above procedure.
The value of the tuning parameters, λ and σ if the kernel is a Gaussian kernel, are chosen to
minimize the out of sample prediction error. However, the only data available to estimate the out of
sample prediction error is subject to censoring, so inverse probability censored weighting is used to
remove the influence of censoring. That is, for a validation dataset of size n∗, the values of the tuning









In this section, we discuss some theoretical properties for the method proposed in Section 2.2. We
introduce some assumptions needed for the proofs and describe situations where these assumptions are
met. Finally, we derive finite sample error bounds, establish P -universal consistency, and determine the
learning rate.
First, we make the following assumptions regarding the censoring distribution. Let
Sc(c|X) = P (C > c|X) be the survival function and gc(c|X) be the density function of the censoring
distribution. We assume that there exist constants 0 < V < Ṽ <∞ such that:
Assumption 2.1. inf
x∈X
Sc(τ − |x) ≥ 2V > 0 .
Assumption 2.2. inf x∈X
t∈XC
gc(t|x) ≥ 2V > 0 and sup
x∈X
t∈XC
gc(t|x) ≤ Ṽ <∞, where XC denotes the
support of C in [0, τ ].
Assumption 2.1 ensures that there is a positive probability of censoring over the observation period
[0, τ ]. Assumption 2.2 ensures that the inverse weight 1/gc(t|x) is well defined. Our next assumption is
with regard to the complexity of the reproducing kernel Hilbert space (RKHS)H. First, recall the
following entropy definition from (Steinwart and Christmann, 2008): Let (T, d) be a metric space and
n ≥ 1 be an integer. Then the nth (dyadic) entropy number of (T, d) is defined as
en(T, d) := inf





where Bd(ti, ε) is the ball of radius ε centered on the point ti. We assume
Assumption 2.3. There are constants q > 1 and 0 < p < 1, such that for all i ≥ 1 the following entropy
bound holds:
ei(id : H 7→ L2(Pn)) ≤ qi−
1
2p , (2.1)
where id : H 7→ L2(Pn) is the embedding ofH into the space of square integrable functions with respect
to the empirical measure Pn and ei(id : H 7→ L2(Pn)) ≡ ei(B1, ‖ · ‖L2(Pn)) where B1 is the unit ball in
H.
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Assumption 2.3 holds for many RKHSs of bounded measurable kernels, including the commonly
used RKHS corresponding to the linear, polynomial, or Gaussian radial basis function kernels (Steinwart
and Christmann, 2008, Section 6.4).
For any loss function L(Y, f), we define the corresponding risk asRL,P (f) = E[L(Y, f(X))] and
the minimal risk asR∗L,P = inf{RL,P (f)|f : X 7→ R is measuarble}. Furthermore, we let f∗ be the
prediction function which achieves the minimal risk, i.e., the best prediction rule minimizing the
expected loss given by LT . Then the following theorem holds.
Theorem 1. Let the censoring distribution be such that assumptions 2.1–2.2 hold and let Ŝc(Y |X) and
ĝc(Y |X) be estimators of the survival and density functions respectively. LetH be an RKHS such that
assumption 2.3 holds. Let f0 ∈ H be any decision function that satisfies ‖LT (Yi, f0(Xi))‖∞ ≤ B0 for
some B0 ≥ B ≡ max(2τ, 2τ2). Then, for any fixed regularization constant λ > 0, n ≥ 1, and η > 0,
with probability not less than 1− 3e−η,






















|Ŝc(Y |X)− Sc(Y |X)|+ |ĝc(Y |X)− gc(Y |X)|
)
,
where W is a constant that depends only p, τ , B, and V .
We can show P -universal consistency using the bound given in Theorem 1 and establish learning
rates, but first we need the following additional assumptions:
Assumption 2.4. For all distributions P on X , there exists some f∗ ∈ L(P ) such that
inff∈H PLT (Y, f(X)) = PLT (y, f
∗(x)).
Assumption 2.5. There exists finite constants s, s′ > 0 such that for any η > 0,
P (‖Ŝc(Y |X)− Sc(Y |X)‖∞ ≥ b1n−1/s) ≤ e−η, (2.2)
and P (‖ĝc(Y |X)− gc(Y |X)‖∞ ≥ b2n−1/s
′
) ≤ e−η, (2.3)
for some constants b1, b2 > 0 which may depend on η.
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Assumption 2.6. Define A2(λ) as the approximation error function:
A2(λ) = λ‖fP,λ‖2H + PLT (Y, fP,λ(X))− PLT (y, f∗(x)), (2.4)
where fP,λ = argminf∈H λ‖f‖2H + PLT (y, f(x)). We assume that there exist constants c0 and
ψ ∈ (0, 1] such that A2(λ) ≤ c0λψ for all λ ≥ 0.
Since the loss function LT is locally Lipschitz continuous, Assumption 2.4 is satisfied ifH is dense
in L(P ) for all distributions P on X . Assumption 2.5 is satisfied for s, s′ > 2 when the survival function
is estimated using the Kaplan-Meier or Cox model based estimates, and the censoring density is
estimated using the method described in equation (2.3). When there exists an f∗ ∈ H minimizing
RLT ,P inH, Assumption 2.6 is met for ψ = 1.
Theorem 2. Assume 2.3–2.6. Let λ→ 0, where 0 < λ < 1, and λmax{1,p}n→∞. Then the prediction
function, f̂D,λ, is P -universally consistent in the sense that
RLT ,P (f̂λ)−R
∗
LT ,P → 0
in probability for any P . Furthermore, it satisfies
RLT ,P (f̂λ)−R
∗















where s̃ = min{1, 1/s, 1/s′}.
2.4 Simulation Studies
In this section, we use simulation studies to demonstrate the performance of WCSVR compared to
three competing methods: the standard proportional hazards (PH) model, an IPCW SVM method similar
to the one proposed in Goldberg and Kosorok (2017), and a rank based SVM method similar to the one
proposed by Van Belle et al. (2011). Specifically, the IPCW SVM decision function is obtained in a





















|Yi − Yj(i) − f(Xi) + f(Xj(i))|+,
where 0 < ν ≤ 1, and subject j(i) is defined to be the subject with the largest survival time smaller than
Yi such that ∆j(i) = 1. The values of κ, and ν are chosen to maximize the concordance index. For each
SVM based method, we use the Gaussian radial basis function kernel, K(x,x′) = exp{−σ‖x− x′‖2},
where the bandwidth σ is a tuning parameter.
The values of the tuning parameters were chosen by a grid search, averaging the results over 5
rounds of 5-fold cross validation. For WCSVR and the IPCW method, the tuning parameters were
chosen from all possible pairs of κ and σ, and the tuning parameters for the rank based method were
chosen from all possible triples of κ, ν and σ2, where,
κ ∈ {2j : j = −4,−3, . . . , 12}, σ ∈ {0.00625, 0.025, 0.10, 0.40, 1.60}, and
ν ∈ {0.1, 0.25, 0.5, 0.75, 1}. For all simulation studies, we assume that the observed times Y fall in an
interval [0, τ ]. The methods will be used to predict a survival time on the interval [0, τ ] since prediction
beyond τ is not supported by the data.
2.4.1 Simulation 1
The first simulation setting is designed to demonstrate the performance of the methods as the
censoring rate increases. The covariate vector X was drawn from a 10-dimensional multivariate normal
distribution with mean 0 and variance matrix Σ with unit variance and all off-diagonal elements equal to
0.3. The failure time followed a Weibull distribution with shape parameter 2 and scale parameter
exp{0.1X1 + 0.2X2 − 0.3X3}. The censoring times follow a lognormal distribution LN(µ, σ2 = 1),
where µ was varied to achieve censoring rates of 20%, 40% and 60%. In this setting, the censoring times
are independent of the covariates, so the Kaplan-Meier derived weights are correctly specified. The Cox
regression derived weights are also correctly specified, but with more flexibility than is needed, resulting
in higher variance weight estimates. The end of study time τ was set as 1.76 which is the 98th percentile
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of the observed failure events when the censoring rate is 60%. This value was chosen to ensure that the
data would support prediction on the range [0, τ ], and so that the results would be comparable across
censoring rates. The models were fit on the log scale of the survival times, Y = log(min{T,C}), but the
average absolute error is calculated on the original scale. We repeated the simulation 100 times for each
of the sample sizes 200, 400, and 800.
Box-plots showing the average absolute error for setting 1 can be found in Figure 2.1. As mentioned
previously, for this failure time distribution, the Cox proportional hazards model is the theoretically most
efficient method, so we use that as a benchmark to compare the SVR based methods. For all sample sizes
and censoring rates, WCSVR had lower average absolute errors than the other SVM based methods. For
sample sizes 400 and 800, it is clear that WCSVR has a smaller loss in performance as the censoring rate
increases. For the most part both the Kaplan-Meier and Cox model based weights perform similarly, but
for a sample size of 200 and a censoring rate of 60%, it is clear that the additional variance in the Cox
model based weights hinder the performance of WCSVR and the IPCW based method.
When the relationship between the covariates and failure time can be described with a simple model,
there is a cost to using the more flexible SVM based methods with the Gaussian RBF kernel. This can be
seen in the results in Figure 2.1 since none of the SVM based methods achieve error rates close to those
of the Cox model; however, this cost seems less pronounced with larger sample sizes or lower censoring
rates.
2.4.2 Simulation 2
The second simulation setting is designed to demonstrate the possible benefits of the flexibility of
the Gaussian kernel with WCSVR. The covariate vector X was drawn from the same distribution as in
setting 1. The failure time followed a Weibull distribution with shape parameter 2 and scale parameter
exp{1.5 + 12 tan
−1(5x1) + (tan
−1(−x42)}. This creates a non-linear relationship between the covariates
and the expected survival time and thus only the SVM based methods using the Gaussian RBF kernel are
correctly specified. The censoring times follow a Weibull distribution with shape parameter 1 and scale
parameter exp{µ− 0.1X1 + 0.2X2 − 0.3X3}, where µ was varied to achieve censoring rates of 40%
and 60%. In this setting, the censoring times follow the proportional hazards assumption, so the Cox
regression derived weights are correctly specified. The end of study time τ was set as 2.66, which is the



































































































































































































































































































































































































































































20% Censoring 40% Censoring 60% Censoring
Figure 2.1: Setting 1. Weibull failure time, log-normal censoring time. Distributions of the average
absolute errors for different sample sizes and censoring rates. Models examined are WCSVR with KM
(WCSVR-KM) or Cox (WCSVR-Cox) model based weights, IPCW-SVR with KM (IPCW-KM) or Cox
(IPCW-Cox) model based weights, SVR with a ranking constraint (Rank), and Cox regression median

























































































































































































































































































































75 40% Censoring 60% Censoring
Figure 2.2: Setting 2. Non-linear failure time, Weibull censoring time. Distributions of the average
absolute errors for different sample sizes and censoring rates. Models examined are WCSVR with KM
(WCSVR-KM) or Cox (WCSVR-Cox) model based weights, IPCW-SVR (IPCW-KM, IPCW-Cox), SVR
with a ranking constraint (Rank), and Cox regression median (Cox). Each box plot is based on 100
repetitions of the simulation for each size of data set.
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Box-plots showing the average absolute errors for setting 2 can be found in Figure 2.2. There is a
non-linear relationship between the covariates and the expected survival time, and the Cox model is
unable to fit this structure. WCSVR appears to be able to learn the non-linear relationship at lower
sample sizes and higher censoring rates than the other methods we examined. Despite being more
flexible, IPCW SVR method does no better than the Cox model when the sample size is small or the
censoring rate is high, and the rank based SVR method seems to only do well for the lower censoring
rate.
2.5 Application
We apply the proposed method to analyze a breast cancer dataset retrieved from the UC Irvine
Machine Learning Repository (Dheeru and Karra Taniskidou, 2017). The goal of the original study was
to use characteristics of the cancer cell nuclei to predict time until recurrence of cancer after tumor
removal surgery. The dataset contains follow-up information for 198 patients exhibiting invasive breast
cancer with no evidence of distant metastases at the time of diagnosis. The variables used in this analysis
include the survival time, recurrence indicator, and ten prognostic variables. Of the 198 patients, there
were only 47 experienced cancer recurrence within the study period, which is a 76% censoring rate. The
prognostic variables are the mean radius, texture, perimeter, area, smoothness, compactness, concavity,
number of concavity points, symmetrY, and fractal dimension of the cell nuclei in the sample. More
information on how these quantities were calculated can be found Wolberg et al. (2018). We compare
different methods including the proposed method to learn prediction functions for time to cancer
recurrence using these prognostic variables. For comparison, the dataset is randomly split into a training
dataset of 148 observations and a testing dataset of 50 observations and this process is repeated 100
times.
Figure 2.3 shows the performance of the SVM based methods using the Gaussian kernel relative to
the PH model. The leftmost plot of Figure 2.3 shows that WCSVR has a higher prediction accuracy than
the Cox model while all other methods have lower accuracy. The rightmost plot shows that all of the
SVM based methods have a higher C-index than the PH model. Regardless of the weighting method
































































































































































































Figure 2.3: Results for breast cancer data.
To understand which prognostic variables are important for prediction, we also apply the SVM
based methods using the linear kernel and the parameter values are extracted and scaled to sum to 1.
Table 2.1 contains the result of this analysis. The results are not directly comparable between the Cox
model and the SVM based methods; however, we can look at the variables that each method identified as
important. The Cox proportional hazards model identified the mean radius and mean perimeter as the
most important variables. The WCSVR and the rank based method also identified mean radius and mean
perimeter as being the most important, but also identified fractal dimension as having an effect. The
IPCW weight based method identified several variables as being moderately important, but the overall
prediction accuracy was quite low.
2.6 Discussion
In this paper we have presented a new method for the analysis of right censored data using support
vector machines. The method incorporates both survival and censoring times which makes complete use
of the available data, leading to good performance even when the censoring rate is high. The method
uses weighting to correct for the likelihood of observations, and we have demonstrated that the resulting
decision rule does not experience bias due to the censoring distribution. We have provided finite sample
19
Table 2.1: Table of standardized coefficients for the breast cancer data over 100 replicates. Values shown
are mean (standard error) of the estimates
WC - KM WC -Cox IPCW - KM IPCW - PH Rank PH model
Radius 0.26 (0.17) 0.26 (0.17) -0.14 (0.09) -0.12 (0.11) 0.21 (0.20) -0.41 (0.03)
Texture -0.02 (0.05) -0.01 (0.03) -0.02 (0.07) 0.00 (0.07) -0.04 (0.06) -0.01 (0.00)
Perimeter -0.27 (0.16) -0.26 (0.17) -0.07 (0.13) -0.04 (0.14) -0.21 (0.17) 0.40 (0.05)
Area -0.07 (0.09) -0.07 (0.08) -0.04 (0.07) -0.01 (0.07) -0.09 (0.07) 0.04 (0.04)
Smoothness -0.07 (0.06) -0.08 (0.07) 0.15 (0.09) 0.16 (0.11) -0.05 (0.04) 0.03 (0.01)
Compactness -0.06 (0.05) -0.06 (0.06) -0.16 (0.07) -0.16 (0.08) -0.05 (0.05) 0.01 (0.02)
Concavity 0.00 (0.04) 0.01 (0.04) -0.05 (0.07) -0.05 (0.07) -0.04 (0.08) -0.02 (0.01)
Concave Points -0.01 (0.05) -0.02 (0.06) -0.03 (0.06) 0.01 (0.07) -0.03 (0.07) -0.01 (0.01)
Symmerty 0.05 (0.05) 0.05 (0.05) 0.10 (0.07) 0.10 (0.08) 0.08 (0.08) -0.01 (0.01)
Fractal Dimension 0.09 (0.06) 0.11 (0.06) 0.06 (0.07) 0.07 (0.08) 0.11 (0.07) -0.04 (0.02)
error bounds and learning rates and proved consistency. We have demonstrated, using simulated and
clinical data, that WCSVR gives a higher survival time prediction accuracy than other SVM based
methods for right censored data and that it is more flexible than the proportional hazards model.
We believe that the weighting methods presented in this work demonstrates an important approach
to making full use of the available data. However, there are still several limitations to overcome and
many potential extensions exist. While WCSVR performs better than other SVR based methods when
the censoring rate is high, we believe that the performance could be improved by introducing a tuning
parameter to control the relative contribution of the survival and censoring times. We have seen evidence
that this tuning parameter could improve performance; however, we have not found a criteria for
choosing the value of this parameter that works well in a majority of situations. The weighting method
could be extended to functions of multiple observations. In the case of the ranking constraint of
Van Belle et al. (2011), the weights which correct for the probability of observation would depend on the
joint distribution of failure and censoring times, which is beyond the scope of this work. We believe that
solving these and other issues is of great interest, and could lead to development of techniques which are
able to better utilize all of the available data.
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CHAPTER 3: BALANCED POLICY EVALUATION AND LEARNING FOR RIGHT CENSORED
DATA
3.1 Introduction
Differences in individual patient characteristics can result in significant heterogeneity in response to
treatment. An individualized treatment rule (ITR) is a function which takes patient specific
characteristics and recommends a treatment. The optimal ITR recommends the treatment that maximizes
the benefit with respect to some clinical outcome. Treatment decisions are made based on published
treatment guidelines which often list several available treatments from which the physician needs to
choose based on expert opinion and personal experience. Using data driven approaches to help inform
decision making can formalize the process and improve patient outcomes. There has been a considerable
amount of effort devoted to the estimation of the optimal ITR (Qian and Murphy, 2011; Zhang et al.,
2012; Zhao et al., 2012, 2014; Cui et al., 2017; Kallus, 2017; Athey and Wager, 2017).
To motivate our approach to estimating ITRs, we consider data from an observational cohort study
of HIV+ patients who take different types of antiretroviral therapy (ART). The nature of this data
presents several challenges to estimating ITRs. First, there are many treatment options. HIV infection is
treated with combination therapies consisting of several drugs from multiple drug classes. Second, the
data are frequently subject to right censoring. One measure of the effectiveness of treatment is the
durability of an ART regimen, which measures how long a patient remains on the same ART. The
durability is predictive of long-term patient morbidity and mortality, but it is prone to loss to follow-up.
Third, the observational nature of the data means that the probability of a patient receiving a particular
treatment may be related to measured and unmeasured factors including comorbid conditions and other
therapies. This confounding by indication can make it difficult to establish causal relationships.
Some early methods for estimating ITRs involved a two step approach that first uses regression
methodology to estimate a conditional mean for the response under each treatment and then recommends
the treatment with the best estimated conditional mean value (Qian and Murphy, 2011). Since these
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methods are based on regression modeling, they can be easily extended to meet the specific requirements
of a wide array of data sources. However, there are a number of concerns about the performance of these
methods (Beygelzimer and Langford, 2009; Zhao et al., 2012). Much of the recent work in ITR
estimation is based on outcome weighted learning (OWL), which reformulates the estimation procedure
as weighted classification (Zhao et al., 2012). The original paper assumed fully observed, binary
treatment data from a clinical trial. Several extensions have relaxed each of these assumptions
individually (Zhao et al., 2014; Wang et al., 2016; Cui et al., 2017; Liang et al., 2018), but none of them
relax all three assumptions simultaneously. Policy evaluation methods are designed to work with
multiple treatments and observational data (Dudı́k et al., 2011; Kallus, 2017; Athey and Wager, 2017).
However, current extensions of these methods to right censored data use multiple weighting approaches,
which results in high variance estimators, or rely on strong assumptions.
In this article, we propose a new method which addresses the shortcomings in existing approaches
with respect to our motivating example. We focus on balanced policy evaluation and learning, an
approach proposed by Kallus (2017). Weighting approaches to policy evaluation can suffer from high
variance when the weights are large. Existing variance reduction methods result in a biased estimator, but
the amount of bias introduced is unknown, making it difficult to optimize the bias-variance tradeoff.
Balanced policy evaluation seeks to quantify the bias-variance tradeoff nonparametrically by finding
weights which minimize a measure of the conditional mean squared error (CMSE). We extend the
balanced policy approach to right censored data by developing an imputation approach which replaces
the censored observations with the conditional expected mean survival time. This allows us to define
weighted and doubly robust estimators for policy evaluation for two or more treatments under right
censoring. By more explicitly quantifying the bias-variance tradeoff and reducing the impact of
censoring via imputation, the proposed approach is able to reduce the variance, leading to more efficient
policy evaluation and learning.
While we focus on a single policy evaluation method, the imputation approach we propose could be
used to extend any ITR estimation method to work with right censored data because it results in an
estimated fully observed outcome vector. We demonstrate that the proposed approach results in
improved performance when compared to existing methods. Nonetheless, the performance of balanced
policy evaluation and learning can suffer in the presence of high dimensional, potentially noisy covariate
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information. We discuss a number of ways to mitigate this issue in the presence of right censored data,
and demonstrate their use in simulation studies.
The remainder of this article is organized as follows. In Section 3.2, we discuss the policy evaluation
approach to estimating ITRs, and introduce an imputation approach for right censored data. In Section
3.3, we develop the theory for the proposed method. Simulation studies are presented in Section 3.4. We
also illustrate our method using data from the University of North Carolina Center for AIDS Research
HIV Clinical Cohort in Section 3.5. The article concludes with a discussion of future work in Section 3.6.
Some technical results and additional simulations are provided in Appendix B.
3.2 Methods
3.2.1 Problem Setup and Notation
Before discussing policy evaluation in the presence of right censoring, we first introduce some
notation and describe policy evaluation and learning adapted to the fully observed survival time setting.
Let X ∈ X be the observed subject-level covariate vector, where X is a d-dimensional vector space, and
A is the treatment, where A ∈ A = [m] = {1, . . . ,m} comes from a finite action space. For each a ∈ A
define T̃ (a) ∈ [0,∞) as the unrestricted failure time that would be observed under treatment a, and let
T̃ = (T̃ (1), . . . , T̃ (m)). In many studies, the unrestricted failure time T̃ is rarely observable due to the
existence of a maximum follow-up time τ <∞. We instead consider T = (T (1), . . . , T (m)), a
truncated version of T̃ at τ , i.e., T (a) = min(T̃ (a), τ) for a ∈ [m]. For a covariate vector x, treatment
a, and failure time T (a) we define the mean-outcome function as µa(x) = E[T (a) |X = x].
In most survival studies there are some subjects for which observation of the failure is precluded by
the occurrence of censoring events. For any treatment a, consider a censoring time C(a) which is
independent of T (a) given X and A. Define the observed time Y (a) = min(T (a), C(a)) and the failure
indicator ∆ = I(T (a) ≤ C(a)). Let the failure time T and censoring time C be generated from
distributions with conditional survival functions S(t |x, a) and G(c |x, a), respectively. The censored
data consist of n observations of covariate, treatment, observed time, and failure indicator:
Dn = {(Xi, Ai, Yi(Ai),∆i)}ni=1. We assume that the data are drawn iid from a fixed distribution:
(X,A,T,C) ∼ P , and that we observe (X,A, Y (A)). This definition of (X,A, Y (A)) implies the
causal consistency assumption of the potential outcomes framework and the stable unit treatment value
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assumption (SUTVA), which ensures that the observed outcome for one subject is unaffected by the
treatment assignments of the other subjects (Rubin, 1980). We also assume that the data satisfy
conditional exchangeability:
Assumption 3.1. T (a) ⊥ A |X for all a ∈ A.
This is commonly referred to as the no unmeasured confounders assumption, where the treatment
decision is not influenced by the outcomes except through their mutual relationship with the observed
covariates X . In our setting, conditional exchangeability is equivalent to there being an unknown
propensity function ϕ which, given covariate vector x, assigns treatment a with probability
ϕa(x) = P(A = a|X = x).
A policy is a map π : X 7→ Θm from the covariate space to a probability vector in the m-simplex,
Θm = {p ∈ [0, 1]m :
∑m
a=1 pa = 1}. For an observation with covariate vector x, the policy π specifies
that treatment a should be administered with probability πa(x). There are two main goals in this
framework. The first goal, known as policy evaluation, is to estimate the average outcome that would be
observed if treatments were assigned according to the policy π. Because the implementation of a bad
policy can be costly or dangerous, new policies are generally evaluated using historical observations
(Thomas et al., 2015). The second goal, known as policy learning, attempts to identify a policy π∗ which
maximizes the expected outcome with respect to some reward. In this article we will assume that larger
outcomes are preferable, and thus the reward would be T or log(T ).
To formally define policy evaluation, consider a policy π for which we wish to estimate the









The SAPE quantifies the average outcome that would have been observed had the treatments been
assigned according to a given policy π. The SAPE is strongly consistent for the population-average
policy effect (PAPE), PAPE(π) = E [SAPE(π)] = E [
∑m
a=1 πa(Xi)µa(Xi)]. If π
∗ is such that
πa(x)
∗ > 0 ⇐⇒ a = argmaxs∈[m] µs(x), then π∗ is an optimal policy. That is, π∗ maximizes
SAPE(π) over all functions X 7→ Θm. For an optimal policy π∗, R(π) = SAPE(π∗)− SAPE(π) is
the regret of π. In policy learning, we wish to find a policy π̂ that minimizes the expected regret.
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3.2.2 Existing Approaches to Policy Evaluation
Current approaches to policy evaluation generally fall into a few categories which are based on mean
outcome modeling, weighting methods, or a combination thereof. The regression-based estimator first










This approach assumes that the regression models for each treatment are correctly specified, which can
be a strong assumption when the number of treatments is large (Zhao et al., 2012).
Weighting-based estimators use covariate and treatment data to find weights, W (π,X1:n, T1:n), that
reweight the outcome data to make it look as though it were generated by the policy being evaluated.







where the weights are often normalized to sum to n. With weights W and regression models µ̂a we can













Wi(Ti − µ̂Ai(Xi)), (3.3)
which can be thought of as denoising the weighted estimator by subtracting the conditional mean from T ,
or debiasing the regression-based estimator using the reweighted residuals.
A common weighting-based approach is inverse propensity weighting (IPW) (Imbens, 2000). By





i=1 πAi(Xi)Ti(Ai)/ϕAi(Xi) |X1:n, A1:n
]
, for ϕ̂, an estimate of the
unknown propensity function ϕ, one can construct weights
W IPWi (π) = πAi(Xi)/ϕ̂Ai(Xi), (3.4)
which gives rise to the estimator ψ̂IPW = ψ̂W IPW(π). Since the propensities appear in the denominator,
small values of ϕ̂ can lead ψ̂IPW to have a large variance. Some ad-hoc solutions for reducing the
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variance exist, such as clipping, where ϕ̂Ai(Xi) is replaced by max{M, ϕ̂Ai(Xi)} for some M , but
these methods generally have the effect of increasing the bias (Cole and Hernán, 2008).
Kallus (2017) proposed a weighting-based estimator which simultaneously controls both the bias
and variance. For a generic weighted estimator ψ̂W (π), consider the conditional mean squared error
(CMSE),
CMSE(ψ̂, π) = E
[(
ψ̂ − SAPE(π)
)2 ∣∣∣∣ X1:n, A1:n] . (3.5)
Balanced policy evaluation takes the CMSE and decomposes it into squared bias and variance
components. The bias term relies on the weights W and the unknown mean outcome function µ. Rather
than directly estimating µ, the balanced policy approach defines a worst case bias by choosing the mean
outcome function from a bounded class of functions that maximizes the squared bias. Once the worst
case bias term has been identified, the variance term is estimated, and balanced policy weights are found
by minimizing the worst case squared bias and variance with respect to the weights W . Additional
details for balanced policy evaluation will be provided in Section 3.2.4.
3.2.3 Extensions to Right Censored Data
Analyzing right censored data without accounting for the missing data results in bias due to
censoring (Fleming and Harrington, 2011), thus consistent policy evaluation requires methods designed
to correct for the bias due to censoring.
Regression-based methods can be extended to right censored data by using regression models
designed for censored data. Common model choices include parametric and semiparametric models such
as the accelerated failure time and Cox proportional hazards models (Kalbfleisch and Prentice, 2011).
However, these models make restrictive assumptions about the structure of the failure time distributions
which are often difficult to verify. Non-parametric models of the survival function have been proposed,
such as the kernel conditional Kaplan-Meier estimate (Dabrowska, 1987) or random forest based
methods (Hothorn et al., 2004; Ishwaran et al., 2008; Zhu and Kosorok, 2012; Steingrimsson et al., 2016;
Cui et al., 2019) which define localized versions of simple survival models, such as the Kaplan-Meier
estimator. Non-parametric models make less restrictive assumptions, but they are less efficient and
unlikely to produce good results in small sample sizes.
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Inverse propensity weighted methods can be extended to right censored data by looking only at the
observed failure times, and weighting based on the probability of observation. Inverse probability of
censoring weighting (IPCW), is motivated by an idea similar to IPW. Since
E[∆ |X,A, T ] = G(T |X,A) we have that E[Y∆/G(Y |X,A) |X,A] = E[T |X,A]. IPCW can be
combined with IPW by defining weights




As long as the models for ϕ̂ and Ĝ are correctly specified, the resulting estimator, ψ̂IPW,IPCWW (π), will be
consistent for the SAPE (Anstrom and Tsiatis, 2001). However, with two weights in the denominator, the
issues with high variance will be compounded.
Balanced policy weights are incompatible with IPCW. Depending on when the IPC weights are
applied, balanced policy weights are either no longer identifiable, or they lose the property of minimizing
the worst case bias and variance. To extend balanced policy to right censored data, we use an imputation
approach similar to one proposed by (Cui et al., 2017). Consider an imputed failure time vector
Ỹi ≡ ∆iYi + (1−∆i)E [Ti | Xi, Ai, Yi, Ti > Yi] , where the censoring times are replaced with the
conditional expected failure time given the covariates, treatment, and the knowledge that the subject
survived at least until time Ci.
Estimating the expected failure time for the censored subjects uses a conditional estimate of the
survival function. Estimates of the survival function can be based on parametric or semiparametric
models, such as the accelerated failure time and Cox proportional hazards model (Kalbfleisch and
Prentice, 2011), or non-parametric models, like the kernel conditional Kaplan-Meier (Dabrowska, 1987)
or random forest methods (Ishwaran et al., 2008). Alternatively, we could use the data to estimate the
best model (or weighted combination of models) with stacked ensemble methods (e.g. Van der Laan et al.
(2007)).
In this article we focus on estimation of the conditional expected failure time using random forest
methods for right censored data because they provide nonparametric estimates with good performance
for higher dimensional data (Cui et al., 2019). Random survival forests (Ishwaran et al., 2008) and
recursively imputed survival trees (RIST) (Zhu and Kosorok, 2012) are based on extensions of random
forests (Breiman, 2001) and extremely randomized trees (Geurts et al., 2006), respectively, where the
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splitting rule for each node is chosen to maximize the log-rank test statistic. (Cui et al., 2019) note that a
splitting rule based on the standard log-rank test statistic can produce biased results because it does not
appropriately control for the censoring distribution, and instead propose a splitting rule which corrects
for the bias due to censoring.
Regardless of the method used to estimate the survival function, given Ŝ(· |X,A), the conditional
expected survival time can be estimated as
Ê [Ti | Xi, Ai, Yi, Ti > Yi] =
∫ τ
Y t dF̂ (t |X,A) + τ Ŝ(τ |X,A)
Ŝ(Y |X,A)
,
and the estimated imputed failure time vector can be defined as
Ŷi = ∆iYi + (1−∆i)Ê [Ti | Xi, Ai, Yi, Ti > Yi] . (3.7)
By using Ŷ in place of T in equation (3.2) we can now define a balanced policy approach to right
censored data.
3.2.4 Balanced Policy Evaluation with Right Censored Data
Recall from equation (3.5) that we defined the CMSE as the squared difference between a weighted










where δij = I[i = j] is the Kronecker delta. Letting εi = Ti − µa(Xi), from Kallus (2017) Theorem 1,
we have that






and, under assumption 3.1,









. This decomposes the CMSE into squared bias and variance
components. The measure of the variance will be given by the norm of weights W TΛW for a positive
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semidefinite (PSD) matrix Λ. Instead of directly estimating the bias term, we find the worst case bias by
maximizing B2(W,π; f) over all functions f ∈ F for a bounded function class F .
To define the worst case bias, we look at functions, f , in the unit ball of a direct product of










where ‖ · ‖Ka is the norm of the RKHS given by the PSD kernel K(·, ·) : X 2 7→ R. Any choice of ‖ · ‖
gives rise to the worst case CMSE objective:






Balanced policy evaluation is given by the estimator ψ̂W ∗(π;‖·‖,Λ) where W ∗(π) = W ∗(π; ‖ · ‖,Λ)
is the minimizer of E2(W,π; ‖ · ‖,Λ) over the space of all weights W that sum to n,
W = {W ∈ Rn+ :
∑n
i=1Wi = n} = nΘn. Specifically,
W ∗(π; ‖ · ‖,Λ) ∈ argmin
W∈W
E2(W,π; ‖ · ‖,Λ). (3.9)
With the imputed survival time vector, Ŷ , and the balanced policy weights, we can define the weighted




















W ∗i (Ŷi − µ̂Ai(Xi)). (3.11)
Next we consider policy learning. For a given policy class Π ⊂ [X 7→ Θm], let π̂ ∈ Π be the policy
which maximizes the balanced policy evaluation estimator, φ̂W , using the weights defined in equation




ψ̂W : π ∈ Π,W ∈ argmin
W∈W






ψ̂W,µ̂ : π ∈ Π,W ∈ argmin
W∈W




It is difficult to maximize the policy π with respect to the full policy class Π = [X 7→ Θm], so it is
common to use a reduced class such as the parameterized policy class
Πlogit = {πa(x;βa) ∝ exp(βa0 + βTa x)}. (3.14)
Using a reduced policy class limits the flexibility of balanced policy learning, but for moderate sample
sizes the reduced complexity can allow for more accurate estimation of π∗.
A high-level description of the proposed method is given in Algorithm 3.1 below.
Algorithm 3.1. Pseudo algorithm for the Balanced Policy Evaluation and Learning with Imputation
Step 1: Use {(Xi, Ai, Yi,∆i}ni=1 to fit a model for the conditional survival function S(t |X,A), and
create the imputed survival time vector, Ŷ , by using Ŝ(t |X,A) to estimate the conditional expected
survival times Ê [Ti | Xi, Ai, Yi, Ti > Yi] for the censored observations.
Step 2: For a norm, ‖ · ‖p,K1:m,γ1:m , and diagonal matrix, Λ, define a policy class Π, and select π0 ∈ Π
Step 3: Find the balanced policy weights associated with ‖ · ‖p,K1:m,γ1:m , Λ, and πi and use the weights
W ∗ to calculate ψ̂W ∗(πi) according to equation (3.10).
Step 4: Calculate the gradient of the policy, πi, with respect to ψ̂W ∗(πi) and use gradient ascent to find
an improved policy πi+1 ∈ Π
Step 5: Repeat steps 3-4 until convergence to an estimated optimal policy π̂.
3.2.5 High Dimensional Considerations
Because the balanced policy weights are defined using a kernel norm ‖ · ‖K, which depends only on
the sample covariate space X , balanced policy evaluation and learning can be sensitive to the presence of
covariates which contain redundant or noisy information. The negative effects of high-dimensional noisy
data can be reduced in several ways including the choice of the kernel norm, and feature elimination,
both of which we detail here.
Recall from equation (3.8) that we defined the norm of a function with respect to the direct product
of RKHSs. One commonly used kernel is the Mahalanobis radial basis function (RBF) kernel
Ks(x, x′) = exp(−(x− x′)T Σ̃−1(x− x′)/s2). (3.15)
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In Lemma 1 point (3) of Kallus (2017), it was shown that, for the norm defined in (3.8), if p = 2 and fa
has a Gaussian process prior, then kernel hyperparameters, such as s and Σ̃, can be selected using the
marginal likelihood principle. Choosing the hyperparameters in this manner reduces the influence of the
unimportant predictors. In simulations this has greatly improved the accuracy of the balanced policy
estimator with respect to evaluation. However, since the redundant or noisy predictors are not eliminated,
the dimension of the search space remains high, which can still adversely impact policy learning.
Reducing the dimension of the search space using variable selection (VS) methods can improve the
performance of policy learning. Nearly any VS method could be used, but to keep our method as general
as possible we examined non-parametric VS methods such as the risk-recursive feature elimination
algorithm (risk-RFE) proposed by Dasgupta et al. (2019). Risk-RFE uses kernel machines to rank the
importance of the features based on the regularized risk. Once the features are ranked in order of
estimated importance, change point estimation methods can be used to identify the important predictors
based on the increase in regularized risk at each step. For additional details see Dasgupta et al. (2019).
In our implementation for high dimensional data, we used methods where tuning hyperparameters
and variable selection required a complete outcome vector. Therefore, these methods were implemented
prior to Step 3 of Algorithm 3.1, but methods which are compatible with right censoring could be
implemented prior to Step 1.
3.3 Theoretical Properties
The properties of the proposed estimator will depend on the method used to estimate Ŷ , so to
facilitate the discussion we make the following assumption:




∣∣∣Ŝn(t |X,A)− S(t |X,A)∣∣∣ = Op(rn).
Assumption 3.2 may seem strong, but it is met for a large number of methods for estimating S(t |X,A).
For example, the assumption holds for AFT and Cox PH models with rn = 1/
√
n. Assumption 3.2 is
also met for non-parametric methods, such as kernel conditional Kaplan-Meier and random forest based
methods. For the kernel conditional Kaplan-Meier, rn = log(nd/(d+4))1/2/n2/(d+4), where d is the
covariate dimension (Dabrowska, 1989). The convergence rate for the bias corrected random survival
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forest method proposed by Cui et al. (2019) depends on the splitting criteria, but the rate for the
theoretically optimal splitting criteria is rn = n−1/(d+2). Convergence rates for other random forest
methods (Ishwaran et al., 2008; Zhu and Kosorok, 2012) have not yet been established, but we believe
that the rates will be similar to those found in Cui et al. (2019).
We show that a convergence rate for Ŝn(t |X,A) is enough to guarantee the convergence rate of Ŷ ;
however, Theorems 12.4 and 12.5 of Kosorok (2008) imply that it is also sufficient to have a convergence
rate for an estimate of the cumulative hazard function, Λ̂(t |X,A).









(1−∆i)W ∗i (Ŷi − Ti)
∣∣∣∣∣ = Op(rn).
where W ∗ = W ∗(π; ‖ · ‖,Λ) are the balanced policy weights.
To prove Lemma 1 we need an additional assumption.
Assumption 3.3. Let Ŷ (i)i = Ê
(i)
n−1(T |Xi, Ai, Yi,∆i), where Ê
(i)
n−1 is based on all observations except











Since Ŷi is based on more information than Ŷ
(i)
i , this assumption should be met provided Ên is
consistent. The proof of Lemma 1 can be found in Appendix B.
Consistent evaluation requires a weak form of overlap between the unknown propensity function and
the target policy being evaluated:




Another requirement is well-specification of the mean-outcome function. For balanced policy evaluation
the mean-outcome function is well-specified if it is in the RKHS product used to compute W ∗(π).
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Otherwise, consistency is also guaranteed if the RKHS product consists of C0-universal kernels, defined
below, such as the RBF kernel.
Definition 1. A PSD kernel K on a Hausdorff X (e.g., Rd) is C0-universal if, for any continuous
function g : X 7→ R with compact support (i.e., for some compact C, {x : g(x) = 0 ⊆ C}) and η > 0,
there exists n′, α1, x1, . . . , αn′ , xn′ such that supx∈X
∣∣∣∑n′j=1 αjK(xj , x)− g(x)∣∣∣ ≤ η.
Theorem 1. Fix π and let W ∗n(π) = W ∗n(π; ‖f‖p,K1:m,γn,1:m ,Λn) with 0 ≺ κI  Λn  κI ,
0 < γ ≤ γn,a ≤ γ ∀a ∈ [m] for each n. Suppose Assumptions 3.1-3.4 hold, Var(T |X) is a.s. bounded,
E[
√
Ka(X,X)] <∞, and E[Ka(X,X)π2A(X)/ϕ2A(X)] <∞. Then the following two results hold:
• If ‖µa‖Ka <∞ for all a ∈ [m], then ψ̂W ∗n(π),Ŷ − SAPE(π) = Op(rn + 1/
√
n),
• If Ka is C0-universal for all a ∈ [m], then ψ̂W ∗n(π),Ŷ − SAPE(π) = op(1).
Corollary 2. Suppose the assumptions of Theorem 1 hold, then
• If ‖µa‖Ka <∞ and ‖µ̂na‖Ka = Op(1) for all a ∈ [m], then
. ψ̂
W ∗n(π),µ̂n,Ŷ
− SAPE(π) = Op(rn + 1/
√
n),
• If Ka is C0-universal for all a ∈ [m], then ψ̂W ∗n(π),µ̂n,Ŷ − SAPE(π) = op(1).






















(1−∆i)Wi(Ŷi − Ti) + ψ̂W ∗n(π),T − SAPE(π).





(1−∆i)Wi(Ŷi − Ti) = Op(rn).
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If ‖µa‖Ka <∞ for all a ∈ [m], then by Kallus (2017) Theorem 3, we have that





− SAPE(π) = Op(rn + 1/
√
n).
If Ka is C0-universal for all a ∈ [m], then by Kallus (2017) Theorem 3, we have that
ψ̂W ∗n(π),T − SAPE(π) = op(1),
and thus ψ̂
W ∗n(π),Ŷ
− SAPE(π) = op(1).
The proof of Corollary 2 follows immediately from Lemma 1, as well as Corollary 4 of Kallus
(2017) in a manner similar to the proof of Theorem 1.
Next, we establish the consistency and learning rates of the balanced policy learner uniformly over








Convergence of these regret quantities require that the best-in-class policy is learnable. We quantify







ρif(Xi), Rn(F) = E[R̂n(F)].





a=1 R̂n(Fa). We also must use a stronger version of the overlap assumption.
Assumption 3.5 (Strong overlap). ∃α ≥ 1 such that P(ϕa(X) > 1/α) = 1 ∀a ∈ [m].
Theorem 3. Fix Π ⊆ [X → Θm] and let W ∗n(π) = W ∗n(π; ‖f‖p,K1:m,γn,1:m ,Λn) with
0 ≺ κI  Λn  κI , 0 < γ ≤ γn,a ≤ γ ∀a ∈ [m], n, and π ∈ Π. Suppose assumptions 3.1-3.2 and 3.5
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hold, |εi| ≤ B a.s. bounded, and
√
Ka(X,X) ≤ Γ ∀a ∈ [m] for Γ ≥ 1. If π̂balancedn is as in (3.12), then
the following results hold:
• If ‖µa‖Ka <∞ for all a ∈ [m], then RΠ(π̂balancedn ) = Op(Rn(Π) + rn + 1/
√
n),
• If Ka is C0-universal for all a ∈ [m], then RΠ(π̂balancedn ) = op(1).
If π̂balanced-DRn is as in (3.13), then the following results hold:
• If ‖µa‖Ka <∞ and ‖µ̂na‖Ka = Op(1) for all a ∈ [m], then
. RΠ(π̂balancedn ) = Op(Rn(Π) + rn + 1/
√
n),
• If Ka is C0-universal for all a ∈ [m], then RΠ(π̂balanced-DRn ) = op(1).
The proof of Theorem 3 follows directly from Assumption 3.2 and Lemma 1, as well as Corollary 7
of Kallus (2017). All the same results hold when replacing Rn(Π) with R̂n(Π) and/or replacing RΠ
with R̂Π.
3.4 Simulation Studies
We have conducted simulation studies to assess the performance of the proposed method in
comparison with existing alternatives. The models we compare are the simple weighted and doubly
robust versions of the balanced policy approach with the imputed failure time vector defined in equation
(3.7), a normalized clipped version of the approach which combines IPW with IPCW as defined in
equation (3.6), and a normalized clipped version of the IPW approach combined with the imputed vector
from (3.7). In all settings, both the optimal and estimated policies are members of the reduced policy
class Πlogit defined in (3.14). The kernel used to define the worst case bias in the balanced policy
approach is the Mahalanobis RBF kernel in equation (3.15), where the hyperparameters are chosen by
the marginal likelihood method using Gaussian process regression. The same kernel is used for all of the
treatments, ‖ · ‖Ka = ‖ · ‖K for all a ∈ [m]. For each setting, the conditional expected survival times, Ŷ ,
are estimated using RIST with the tuning parameter settings suggested in Zhu and Kosorok (2012).
Propensity scores are estimated using a correctly specified Gaussian process classifier. Due to different
censoring mechanisms, the weights used for IPCW are estimated differently for each setting. For the first
setting the censoring weights are estimated using RIST with the recommended tuning parameter settings.
35
For the second setting the censoring weights are estimated using the correctly specified accelerated
failure time (AFT) model. A testing dataset with size 10,000 is used to approximate the population regret
(PAPE(π∗)− PAPE(π̂)). For each setting the log survival time is used to estimate the optimal policy
on simulated datasets of size N = 500, 1000, and 2000. Each simulation is repeated 100 times.
3.4.1 Simulation Settings
Our first setting is a slight modification of the setting found in Kallus (2017). To begin, we sample
the covariate vector from a multivariate normal distribution X ∼ N (0,Σd), where d = 10 and Σd is
compound symmetric covariance with diagonal elements of 1 and off diagonal elements of 0.2. The
treatments are assigned with probabilities which depend on the first two elements of of X . Specifically
A |X ∼Multinoulli(p1(X), . . . , p5(X)) where pa(X) ∝ N((X1, X2)−Xa, I2×2) for a ∈ [m],
X1 = (0, 0), X2 = (1, 0), X3 = (0, 1), X4 = (−1, 0), and X5 = (0,−1). The unrestricted failure
times are drawn from a log-normal distribution where log(T̃ ) |A ∼ N(µA(X), σ2 = 1) where
µa(x) = exp(1)− exp(1− 1/‖x− χa‖2), and χa = (Re, Im)(e−i2πa/5/
√
2) for a ∈ [5],
εi ∼ N(0, 1), and (Re, Im) are the real and imaginary components respectively. The observed failure
time T = min(τ, T̃ ), where τ = 3.5. This mean outcome process results in an optimal treatment policy
consisting of 5 equal sized wedges arranged radially about the origin. The censoring times are drawn
from a log-normal distribution where log(C) |A ∼ N(µC(X), σ2 = 2) where
µC(x) = (5/2)− (1/2) exp(1− 1/‖X1 +X2‖2)). The censoring rate is approximately 45%.
In the second setting, the failure times are drawn from log-normal distributions where the treatment
effect has both prognostic and prescriptive elements. The 10-dimensional covariate vector, X , is drawn
from a uniform(−1, 1) distribution with a compound symmetric covariance structure by first drawing
from a multivariate normal distribution N (0,Σd) where Σd is the same as in setting 1. The CDF
transformation was applied to the normally distributed covariates which where then scaled to be within -1
and 1. The treatments are assigned with probabilities which depend on the first three elements of of X ,
where A |X ∼Multinoulli(p1(X), . . . , p3(X)) where pa(X) ∝ N((X1, X2, X3)−Xa, I3×3) for
a ∈ [3], X1 = (−0.5,−0.5, 0.4), X2 = (0, 0,−0.75), X3 = (0.5, 0.5, 0.4). The unrestricted failure
times are drawn from a log-normal distribution where
log(T̃ ) = 0.2− 0.6X1 + 0.2X2 + 0.4X3 + µa + ε, where µ1 = 0.2X1 − 0.3X2, µ2 = 0.1 + 0.1X3,
µ3 = −0.1− 0.2X1 + 0.4X2− 0.2X3, and ε ∼ N(0, σ2 = 1). The failure times T = min(τ, T̃ ), where
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τ = 1.5. The censoring times are drawn from a log-normal distribution which depends on the assigned
treatment, where log(C) = 0.6− 0.4X1 + 0.3X2 + 0.8X3 + νa + ε, with ν1 = −0.1X1 − 0.2X2,
ν2 = 0.1X2, ν3 = −0.1 + 0.3X2 − 0.4X3 and ε ∼ N(0, σ2 = 1). The censoring rate is about 45%.
3.4.2 Simulation Results
The results for setting 1 can be found in Figure 3.4. This setting is designed to have mismatch
between the unknown propensity function and the optimal policy such that the inverse propensity
weights are large, resulting in high variability for the IPW with IPCW, and IPW with Imputation
approaches. As expected, the increased variance of the IPW based estimators results in reduced
performance. The more stable balanced policy with imputation approach performs better than the other
approaches. In this setting the feature elimination method effectively eliminates noise variables, even for
small sample sizes, which increases performance over the methods using a higher dimensional feature
space. We also examined doubly robust approaches for each of the methods, but the mean model was not
accurate enough to improve performance over the simple weighted methods. The results for the doubly
































































































































































Figure 3.4: Boxplots showing estimated population regret for setting 1. Smaller is better. IPW+IPCW:
IPW combined with IPCW; IPCW+Ŷ : IPW with imputed outcome vector; BP+Ŷ : Balanced policy with
imputed outcome vector. Variable selection used risk-RFE to remove variables.
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The results for setting 2 can be found in Figure 3.5. Again the higher variability of the IPW with
IPCW, and IPW with Imputation approaches reduced performance when compared to the balanced
policy approach. The doubly robust approaches for the balanced policy with imputation and IPW with
Imputation increased performance compared to the simple weighted versions for small sample sizes. We
examined the effect of feature elimination in this setting, but the method frequently eliminated important


































































































































































Figure 3.5: Boxplots showing estimated population regret for setting 2. Smaller is better. IPW+IPCW:
IPW combined with IPCW; IPCW+Ŷ : IPW with imputed outcome vector; BP+Ŷ : Balanced policy with
imputed outcome vector. Doubly robust versions used the correctly specified AFT model for µ̂.
3.5 Application to HIV Study
We apply the proposed method to analyze data from the UNC CFAR HIV Clinical Cohort (UCHCC).
In the UCHCC study, patients were followed from initiation of an integrase strand transfer inhibitor
(INSTI) in combination with at least two other antiretroviral (ARV) agents from at least one other ARV
therapy class representing current standard of care for initial ART in high income clinical settings.
Patients were followed until the first of ART modification or discontinuation, death, loss to follow-up, or
administrative censoring. The study data included 957 HIV-infected patients who were 72% male, 62%
black, 29% white, 9% Hispanic or other races/ethnicities. The median age at treatment initiation was 44
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years, 50% were men who have sex with men, and 9% had a history of injection drug use. At INSTI
initiation (baseline), the median CD4 cell count was 514 cells/mm3 (range 9 to 2970.0) and the median
HIV RNA level was 1.8 log10 copies/mL (range 1.3 to 7.6). The median number of prior antiretroviral
(ARV) compounds was 3 (range 0 to 17) and 29% had no prior ARV experience. The INSTI regimen
was chosen by providers and patients based on clinical indication and included in all cases one integrase
strand transfer inhibitor (INSTI) and two or more nucleoside reverse-transcriptase inhibitors (NRTIs).
The covariates include age, male (yes, no), race (black, white, or other), men who have sex with men
(yes, no), injection drug use (yes, no), baseline CD4 count, baseline viral RNA level, an indicator if
baseline viral RNA is undetectable, the number of prior ARV agents, and an indicator if the patient is
treatment naı̈ve. Categorical variables are transformed into dummy variables, resulting in an
11-dimensional covariate vector X .
The treatment regimens of interest are Raltegravir (RAL), Elvitegravir (EVG), and Dolutegravir
(DTG), each with 2+ NRTIs. The primary outcome of interest is time to the discontinuation of the initial
INSTI regimen, which is defined as either a change in the INSTI agent or discontinuing ART for more
than two weeks. The compounds under consideration received FDA approval at different times, so the
maximum follow-up time is different for each regimen. The left plot in Figure 3.6 shows the
Kaplan-Meier curves for the UCHCC data by treatment over the unrestricted follow-up window. This
plot indicates that there may be large treatment differences for the longer follow-up times, but we chose
to limit our analysis to 2.5 years (913 days) of follow-up time. This time period was chosen because it is
near the 98th percentile of observed treatment discontinuations for the regimen with the least follow-up
time, which ensures sufficient data coverage to support the analysis.
Among the 957 study subjects, 416 (43%) were observed to discontinue treatment, and 319 (33%)
were censored due to loss to follow-up during the first 2.5 years. The 222 (23%) patients still being
followed after 2.5 years were administratively censored.
We applied balanced policy evaluation and learning to the UCHCC data using all available variables
with the kernel defined in (3.15) and the policy class in (3.14). The estimated optimal treatment strategy
identified by balanced policy evaluation and learning was to treat every patient with DTG and 2+ NRTIs.
Each of the three INSTIs evaluated in these analyses have different barriers to resistance evolution,
tolerability profiles and dosing frequency, likely affecting the durability of the regimen differentially
across different patient groups. Additional analyses stratified by whether patients were ART naive at
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INSTI initiation or by age at INSTI initiation, supported the findings of the primary analyses, the details
of which may be found in Appendix B.




























































Figure 3.6: The left plot shows the estimated marginal survival curves for each treatment over the entire
follow-up period. The right plot shows the estimated marginal survival curves for each treatment over the
restricted follow-up period.
In order to see how our method performs in comparison to existing methods on realistic data when
meaningful subgroup effects are present, we modified the data to remove the baseline differences
between treatments which allows ITR estimation methods to highlight existing treatment response
heterogeneity. Specifically, a constant scaling factor was applied to the observed times for each of the
treatments so that the marginal treatment effect difference between any two treatments was negligible.
Due to the effects of differential censoring rates between treatments, the average policy effect was
estimated using the regression-based estimator (3.1) where the mean process µ̂ was estimated using
RIST.
For this analysis we used a reduced set of predictors which were identified by risk-RFE as being
most likely to have meaningful subgroup effects. The predictors were age, treatment naı̈ve status,
baseline CD4, baseline RNA, and an indicator if the baseline RNA is undetectable. The conditional
expected survival times, Ŷ , and the censoring probabilities used for IPCW were estimated using RIST
with the tuning parameter settings suggested in Zhu and Kosorok (2012). Propensity scores were
estimated using a Gaussian process classifier. The balanced policy evaluation again used the kernel
defined in (3.15) and the policy class in (3.14).
For comparison between methods, we estimate the optimal policy with a cross-validation type
analysis. Specifically, the data are partitioned into ten roughly equal-sized parts. For each method under
consideration, we estimate the optimal policy on nine parts of the data, and then compute several
estimates of the SAPE using the remaining tenth part. By applying the above procedure, holding out a
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different part of the data each time, we were able to get out-of-sample predictions which should better
represent expected optimal SAPE for future subjects. This approach was applied to 100 different
partitions of the data and the results are presented in Table 3.2 and Figure 3.7.
We compare the balanced policy with imputation approach to several other methods. The
regression-based method as defined in equation (3.1) with µ̂ estimated using RIST, and two weighted
methods as defined in equation (3.2). The weighted methods are: IPW with IPCW using the weights
defined in equation (3.6), and IPW with imputation using Ŷ and the weights defined in equation (3.4).
From Table 3.2, we observe that the proposed approach produces policies with larger mean
estimated SAPE with smaller standard errors across all three evaluation criteria. The policies found by
the regression-based estimator had high estimated SAPE with respect to its corresponding criteria,
ψ̂Reg(π̂), but low estimated SAPE with respect to the weight based criteria, ψ̂W IPW(π̂) and ψ̂W IPW,IPCW(π̂).
The proposed method was able to find policies with high estimated SAPE for all criteria, indicating that
the policies found were truly the best in terms of SAPE, as their improvement was insensitive to the
choice of validation estimation method.
Table 3.2: Analysis of modified HIV data: Mean (sd) of estimated SAPE (Days on treatment).
Method ψ̂Reg(π̂) ψ̂W IPW(π̂) ψ̂W IPW,IPCW(π̂)
Reg 667 (0.63) 608 (12.1) 601 (12.7)
IPW+IPCW 658 (2.37) 630 (12.0) 617 (14.1)
IPW+Ŷ 660 (2.26) 626 (12.5) 620 (15.7)
BP+Ŷ 667 (0.43) 649 (6.1) 647 (6.9)
Reg: Regression-based approach; IPW+IPCW: IPW combined with IPCW; IPCW+Ŷ : IPW with
imputed outcome vector; BP+Ŷ : Balanced policy with imputed outcome vector.
Table 3.3: Analysis of modified HIV data: Mean (sd) of the percentage of subjects assigned to each
treatment.
Method RAL EVG DTG
Reg 42.1% (1.62) 51.0% (1.75) 6.9% (0.77)
IPW+IPCW 32.2% (3.98) 57.4% (3.25) 10.4% (1.83)
IPW+Ŷ 36.6% (3.38) 54.9% (3.02) 8.5% (2.10)
BP+Ŷ 48.1% (1.17) 49.4% (0.94) 2.5% (0.73)
Reg: Regression-based approach; IPW+IPCW: IPW combined with IPCW; IPCW+Ŷ : IPW with
imputed outcome vector; BP+Ŷ : Balanced policy with imputed outcome vector.
Table 3.3 shows the mean and standard deviations of percentage of subjects that were assigned to








































































































































Figure 3.7: Boxplots showing the estimated SAPE for the modified HIV data. Larger is better. Reg:
Regression-based approach; IPW+IPCW: IPW combined with IPCW; IPCW+Ŷ : IPW with imputed
outcome vector; BP+Ŷ : Balanced policy with imputed outcome vector.
standard deviation of the treatment assignment percentages is smallest for the proposed method,
indicating that it is less sensitive to small perturbations of the data when compared to the other
approaches. The variability was largest for the inverse weighted methods which is likely a result of the
higher variance of these estimators. The censoring rates were modest for RAL and EVG, but high for
DTG. Estimating the average treatment effect in the presence of high censoring likely led to an unstable
estimate and we believe that adjusting based on this estimate led to the unusually low numbers of
subjects assigned to DTG.
3.6 Discussion
The proposed method appears to be more effective at finding optimal treatment policies, when
compared to adapting previous methods to the right-censored setting. The use of unbiased weighted
estimators is likely to result in high variance estimates of the SAPE which can complicate the process of
finding the policy that is optimal for the population of interest. The proposed method uses a balanced
policy evaluation and learning approach combined with imputation of the censoring times to reduce the
variance of the estimator. Both of these approaches are likely to increase the bias, especially for small
sample sizes. However, our results show that the reduction in variance offsets the increased bias and
allows for more effective training of an optimal treatment policy.
The imputation approach that we propose can be used to extend any policy evaluation method to
right censored data. In the simulation studies, we demonstrated that combining inverse propensity
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weighting with the imputation approach leads to better performance when compared with the method
that uses both inverse propensity and inverse probability censoring weights. We showed that the
imputation approach is compatible with any consistent estimate of the conditional survival or cumulative
hazard function. We proved that the convergence rates for the conditional expected failure times is of the
same order as the convergence rates for the conditional survival or cumulative hazard function estimator.
There are a number of ways in which the proposed method may be improved or extended. As
currently formulated, the proposed method is limited to comparatively small datasets, both in terms of
number of observations and the dimension of the covariate space. Like the original balanced policy
evaluation method, the proposed method is more computationally intensive than existing approaches.
There may be more efficient optimization procedures, such as alternating descent or boosting with a
faster approximate method that could allow the proposed method to be applied to larger datasets.
Additionally, when no parametric or semiparametric relationship can be assumed for failure time
distribution, the convergence rate of the conditional expected survival times can be quite slow, especially
when the number of covariates are large. We have discussed some potential solutions, but a more
principled approach may be able to further increase the performance. It would also be of interest to
extend our approach to dynamic treatment regimes where we wish to identify an optimal treatment
sequence in a censored survival setting.
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CHAPTER 4: POLICY EVALUATION FOR CONTINUOUS TREATMENTS WITH RIGHT
CENSORED DATA
4.1 Introduction
Dose finding is an important consideration for several medications. In anti-depressant drugs such as
venlafaxine, increasing the dose is associated with a greater therapeutic effect, but it has also been shown
to increase the number or severity of side effects (Rudolph et al., 1998). In medications such as Warfarin,
there is a narrow therapeutic window within which the drug is effective, and incorrect dosing in either
direction can contribute to a high rate of adverse effects (The International Warfarin Pharmacogenetics
Consortium, 2009). The optimal dose of a drug may depend on patient-specific characteristics, such as
genetic markers or clinical measurements. In these situations it would be advantageous to be able to
tailor the dose based on these characteristics. An individualized dose rule (IDR) is a function which takes
patient specific characteristics and recommends a dose. An optimal IDR is a rule that recommends the
dose that maximizes the benefit with respect to some clinical outcome. Dosing decisions are often made
through trial and error based on expert opinion and a physician’s personal experience. Informing the
decision making process with data driven individualized dose recommendations has the potential to
improve patient outcomes. Personalized dose finding methods have been of increasing interest recently
(Kallus and Zhou, 2018; Chen et al., 2016).
In many biomedical applications the outcome of interest is subject to censoring, but current methods
for estimating dose finding IDRs assume that the outcome is full observed. Right censored data is
common in cancer trials where dosing of some medications has been shown to significantly impact
survival rates (Heo et al., 2013). Even when the outcome is not subject to censoring, it may be
advantageous to formulate the objective as a time to event outcome which is subject to right censoring.
For very complicated interactions between medications and clinical outcomes it may be difficult to find
the optimal dose for a large number of subjects. By instead looking at the time between initiating the
medication and finding a therapeutic dose we may be able to identify an optimal initial dose which will
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minimize the time between initiating a medication and finding a therapeutic dose. Any subjects for
which a therapeutic dose is not found by the end of the study may be considered to be right censored.
Some early methods for estimating individualized treatment rules involved a two step approach
based on regression methodology. First, regression models are used to estimate the mean response
conditional on the observed covariates and their interaction with treatment. Second, the method
recommends the treatment with the optimal estimated conditional mean value (Qian and Murphy, 2011).
Since these methods are based on regression modeling, they can be easily extended to meet the specific
requirements of a wide array of data settings, including dose finding studies and right censoring.
However, there are a number of concerns about the performance of these methods (Beygelzimer and
Langford, 2009; Zhao et al., 2012). More recent work in IDR estimation is based on outcome weighted
learning or policy evaluation (Kallus and Zhou, 2018; Chen et al., 2016). In the discussion of Chen et al.
(2016), the authors highlight the importance for an IDR method for right censored data, but as far as we
are aware no such methods have been published.
In this article, we propose a new method for estimating IDRs in the presence of right censoring. Our
method is based on an extension of balanced policy evaluation and learning to continuous treatments.
Balanced policy evaluation and learning is an approach originally proposed by Kallus (2017), and later
generalized to continuous treatments in Kallus (2019). Balanced policy evaluation seeks to quantify the
bias-variance tradeoff nonparametrically by finding weights which minimize a measure of the
conditional mean squared error. We extend the balanced policy approach to right censored data using an
imputation approach which replaces the censored observations with the conditional expected mean
survival time. By more explicitly quantifying the bias-variance tradeoff and reducing the impact of
censoring via imputation, the proposed approach is able to reduce the variance, leading to more efficient
policy evaluation and learning.
The remainder of this article is organized as follows. In Section 4.2, we discuss the policy evaluation
approach to estimating IDRs, and introduce an imputation approach for right censored data. Simulation
studies are presented in Section 4.3. We also illustrate our method using data from The International
Warfarin Pharmacogenetics Consortium 4.4. The article concludes with a discussion of future work in
Section 4.5. Some technical results and additional simulations are provided in Appendix C.
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4.2 Methods
4.2.1 Problem Setup and Notation
To begin, we introduce some notation and describe policy evaluation and learning adapted to
continuous treatments. We consider an observational dataset consisting of subjects described by a patient
level covariate vector X = (X1, X2, . . . , Xd)T ∈ X . Each subject is observed to have received
treatment A ∈ A, where the probability of receiving a specific treatment is allowed to depend on X . In
every dose finding application, there will be a bounded range of safe doses from which the treatments
will be chosen, and so we assume w.l.o.g. that A ⊆ [0, 1]. Let T̃ (a) ∈ [0,∞) be the unrestricted failure
time after receiving dose a. Many studies have a maximum followup time, which we call τ , beyond
which observation of the failure time is not possible. Thus the unrestricted failure time T̃ (a) is rarely
observable, and instead we consider a truncated failure time T (a) = min(T̃ , τ). Under the
Neyman-Rubin causal framework, T (a) denotes the potential outcome of a unit had it received treatment
a. For a covariate vector x, treatment a, and failure time T (a), we define the mean-outcome function as
µ(x, a) = E[T (a) |X = x].
In most survival studies there are some subjects for which observation of the failure is precluded by
the occurrence of a censoring event. For any treatment a, consider a censoring time C(a) which,
conditional on X and A, is independent of T (a). Define the observed time Y (a) = min(T (a), C(a))
and the failure indicator ∆ = I(T (a) ≤ C(a)). The censored data consist of n observations of covariate,
treatment, observed time, and failure indicator: {(Xi, Ai, Yi(Ai),∆i)}ni=1. We assume that the data are
drawn iid from a fixed distribution: (X,A, T (A), C(A)) ∼ P , and that we observe (X,A, Y (A)).
Defining the observed data in this manner implies the causal consistency assumption of the potential
outcomes framework as well as the stable unit treatment value assumption which ensures that the
observed outcome for each subject depends only on its covariate and treatment values (Rubin, 1986). We
also assume that the data satisfy conditional exchangeability:
Assumption 4.1. T (a) ⊥ A |X for all a ∈ A.
Conditional exchangeability is commonly referred to as the no unmeasured confounders assumption,
where each factor that affects both the treatment decision and the outcomes is contained in the covariate
vector X . In our setting, conditional exchangeability is equivalent to there being an unknown propensity
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function ϕ, where ϕ(a|X) is the conditional density of A = a given X . This quantity, sometimes
referred to as a generalized propensity score, extends the discrete propensity score to the continuous
setting (Hirano and Imbens, 2004).
A policy is a map d : X 7→ [0, 1] from the covariate space to a recommended dose. The goal of
policy evaluation is to estimate the value of implementing a policy
V ∗(d) = E[T (d(x))]. (4.1)
The value function V (d) is the expected failure time that would be observed if dose levels in the
population were assigned according to the policy d. In this article we will assume that larger outcomes
are preferable, and thus higher policy values are better. However, the methods we present will still be
applicable when smaller outcomes are preferable.




That is, we wish to find the policy that maximizes the benefit with respect to some clinical measure (e.g.
survival time).
4.2.2 Current IDR Estimation Methods








A common approach is to use a plug-in type estimator based on a regression model for the mean









Similar approaches have been used to estimate individualized treatment rules in a variety of applications
(Rosenwald et al., 2002; Van’t Veer and Bernards, 2008; Qian and Murphy, 2011). Regression-based
methods can achieve good performance when the underlying disease mechanism can be well
approximated by an efficient model. However, the consistency of these methods requires that the
regression models are correctly specified. Correct specification of these models relies not only on the
assumptions about the failure time distribution, but also the relationship between the covariates and the
treatment. Both types of misspecification may be difficult to detect in practice.
Both Chen et al. (2016) and Kallus and Zhou (2018) proposed methods for estimating IDRs based














where K(u) is a one-dimensional kernel with bandwidth h. The inverse propensity weights correct for
the likelihood of observing a subject based on their covariate and treatment values, and the
1-dimensional kernel allows the method to borrow strength across subjects which received a similar dose
level. The method proposed by Chen et al. (2016) is equivalent to assuming that K is the triangular
kernel, and formulating the optimal IDR as the solution to a weighted classification problem in a manner
similar to outcome weighed learning (OWL) (Zhao et al., 2012). This approach bypasses the evaluation
step and directly learns an estimated optimal policy d̂OWL. Kallus and Zhou (2018) assume that the kernel
function K(u) symmetric about the origin and that it integrates to 1, but otherwise leave the kernel
unspecified, and choose the estimated optimal policy as d̂IPW = argmaxd ψ̂IPW(d). Both approaches are
sensitive to the choice of bandwidth h. Chen et al. (2016) choose the bandwidth via cross validataion
while Kallus and Zhou (2018) propose a method for estimating the asymptotically optimal bandwidth.







where the weights W = W (d;X1:n, A1:n) are based on the policy as well as covariate and treatment
data. It is common practice in causal effect estimation to normalize the weights such that they sum to n
(Austin and Stuart, 2015). Weighted estimators can have high variance when the weights are large, which
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happens when there are small quantities in the denominator of the weights. This increased variance can
lead to reduced performance of the estimator. One proposed solution to this issue is clipping the weights,
where the clipped weights W ci = min{Wi,M} for some constant M . Clipping the weights decreases
the variance, but it also introduces an unknown amount of bias into the estimator. Balanced policy
evaluation and learning is an alternative weighting approach originally proposed in Kallus (2017) which
takes a more principled approach to reducing the variance while also controlling the bias.
4.2.3 Balanced Policy Evaluation for Dose Finding
Balanced policy evaluation as originally proposed in Kallus (2017) assumed that there were a finite
number of treatment values. Kallus (2019) introduced a generalized framework for balanced policy
evaluation, and the continuous treatment setting may be considered a special case of this general
framework. We now outline the balanced policy evaluation method adapted to continuous treatments.
For a weighted estimator ψ̂W (d), the risk of the estimator can be measured as the conditional mean
squared error (CMSE) based on the policy, covariate, and treatment information.
CMSE(ψ̂W ,d) = E
[(
ψ̂W (d)− V (d)
)2 ∣∣∣∣X1:n, A1:n] . (4.6)
The objective of balanced policy evaluation is to choose weights W that minimize the CMSE. If we
assume that the failure times, Ti = µ(Xi, Ai) + εi, can be represented as the sum of a mean process and
independent error such that E[εi |Xi, Ai] = 0 and E[ε2i |Xi, Ai] = σ2i <∞. Then we can decompose
ψ̂W (d)− V (d) as






















Note that the first term in equation (4.7) is equivalent to E[ψ̂W (d)]− V (d). Using this decomposition
and Assumption 4.1 we can define an alternative form of the CMSE


















µ(Xi, a)d(Wiδ(a−Ai)− δ(a− d(Xi))2







i is the variance of the estimator ψ̂W (d). Since the quantities µ and Σ are
unknown, we can not directly find weights that minimize the CMSE. Instead we choose the balanced
policy weights to minimize the bias and estimated variance over a large number of functions f ∈ F
where we assume that µ ∈ F . Let F be the unit ball of a reproducing kernel Hilbert space (RKHS) with





B(f ;W,d) = ‖B(·;W,d)‖∗K,
where ‖ · ‖∗K is the dual norm of the RKHS. This gives us an upper bound on the bias over all functions
in F using only the information in the covariate and treatment values (Xi:n, Ai:n).
By assuming that F is contained in a RKHS, we are imposing a smoothness constraint on µ which
allows us to compare observations that are close in the covariate and treatment space. This is similar to
the motivation behind the 1-dimensional kernel used in the IPW estimator in equation (4.5).
The choice of RKHS used to define the weights can have a large effect on the performance of
balanced policy evaluation. Kallus (2017) Lemma 1 showed that kernel hyperparameters can be selected
using the marginal likelihood method. For example, consider the Mahalanobis radial basis function
(RBF) kernel
Ks(x, x′) = exp(−(x− x′)TS−1(x− x′)/s2). (4.8)
The parameters S and s can be adapted to the specific situation based on the data. This allows the kernel
to more accurately represent the structure of the observed data.
To characterize the variance of the weighted estimator, we estimate Σ̂ = diag(σ̂21, . . . , σ̂
2
n) based on
a regression model. Combining the upper bound for the bias with Σ̂, we can define the “worst-case”
CMSE objective as







The balanced policy weights are found as the vector of weights which minimize the “worst-case” CMSE.
Thus the balanced policy estimator is given by ψ̂W ∗(d; ‖ · ‖, Σ̂) where
W ∗(d; ‖ · ‖, Σ̂) ∈ argmin
W∈W
E2(W,d; ‖ · ‖, Σ̂).
andW = {W ∈ Rn+ :
∑n
i=1Wi = n} is the space of all weights W that sum to n. The balanced policy
weights can be found as the solution to a quadratic optimization problem.
By selecting the weights in this manner, balanced policy evaluation is able to reduce the variance of
the estimator within the context of a bias-variance tradeoff. The bias-variance tradeoff can be further
controlled by replacing Σ̂ with a matrix Λ = aΣ̂ where a > 1 favors estimators with less bias, and a < 1
favors estimators with lower variance.
4.2.4 Extension to Right Censored Data
To extend IDR estimation methods to right censored data, Chen et al. (2016) proposed inverse
probability of censoring weighting (IPCW) as a possible approach. The motivation for this approach is
similar to that of IPW in that the IPCW weights correct for the probability of observing a failure time.
While IPC weights have been used to extend other estimators to right censored data, they are not
compatible with the balanced policy weighting approach.
Instead we look at using a regression-based approach to correct for the missing data due to
censoring. The approach we propose is similar to the methods proposed by Cui et al. (2017), as well as
in chapter 3. Given a model of the expected failure time, we can replace the censoring times with their
expected values conditional on the observed data. Define the imputed failure time vector
Ŷi = Ê [Ti | Xi, Ai, Yi,∆i]
= ∆iYi + (1−∆i)Ê [Ti | Xi, Ai, Yi, Ti > Yi] , (4.9)
where the censoring times are replaced with the conditional expected failure time given the covariates,
treatment, and the knowledge that the failure time occurred after the censoring time.
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The expected failure time can be calculated using an estimate of the survival function of the failure
time distribution, Ŝ(·|X,A), conditional on the covariate and treatment data as
Ê [Ti | Xi, Ai, Yi, Ti > Yi] =
∫ τ
Y t dF̂ (t |X,A) + τ Ŝ(τ |X,A)
Ŝ(Y |X,A)
, (4.10)
where F (·|X,A) = 1− S(·|X,A) is the distribution function of the failure time distribution.
We are using a regression-based approach to imputation, and thus all of the concerns about the
regression-based estimator defined in equation (4.4) also apply to the imputation approach. Specifically,
the imputation approach will not result in a consistent method if the regression model is misspecified.
Parametric and semiparametric models such as the accelerated failure time and Cox proportional
hazards models are frequently used for right censored data (Kalbfleisch and Prentice, 2011). However,
these models make restrictive assumptions about the structure of the failure time distribution which may
limit their applicability in some settings. For these methods to be consistent, we must also correctly
specify the relationship between the covariates and the treatment (i.e. linear, quadratic, etc.) and
construct the model matrix accordingly.
Nonparametric estimates are more likely to be correctly specified for any given dataset because they
impose fewer and less restrictive assumptions, but this comes at the cost of reduced efficiency. The
kernel conditional Kaplan-Meier estimate uses kernel weights based on the covariate values to define a
localized version of the Kaplan-Meier estimator (Dabrowska, 1987). Several nonparametric estimates of
the survival function are based on extensions of random forest methods to right censored data, including
Random survival forests (Ishwaran et al., 2008) and recursively imputed survival trees (Zhu and Kosorok,
2012). Cui et al. (2019) proposed a bias corrected splitting rule for random forest based survival methods
and also established the convergence rate of the survival function estimate found by their method. For
nonparametric methods, we need not specify the relationship between the covariates and the treatment.
Instead, a data driven approximation of the relationship can be found by treating the dose value as an
additional covariate.
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4.2.5 Balanced Policy Learning with Right Censored Data
With the balanced policy weights, W ∗ = W ∗(d, ‖ · ‖,Λ), and the imputed survival time vector we








W ∗i Ŷi. (4.11)
Given a policy class D, the estimated optimal policy, d̂ ∈ D, is the policy which maximizes the balanced






: d ∈ D,W ∈ argmin
W∈W
E2(W,d; ‖ · ‖,Λ)
}
. (4.12)
Theorem 5 of Kallus (2017) provides a method for finding the gradient of ψ̂
W,Ŷ
(d) with respect to the
policy d̂.









By applying the chain rule, we can find the parameters β which yield the optimal policy with
gradient-based optimization algorithms. Algorithm 4.1 contains a high level description of the proposed
approach.
Algorithm 4.1. Pseudo algorithm for the Balanced Policy Evaluation and Learning with Imputation
Step 1: Fit a model for the conditional survival function S(t |X,A) using {(Xi, Ai, Yi,∆i}ni=1.
Calculate the imputed survival time vector, Ŷ , by the equations defined in (4.9) and (4.10).
Step 2: Use {Xi, Ai, Yi}ni=1 or {Xi, Ai, Ŷi}ni=1 to select hyperparameters associated with ‖ · ‖K, or Λ.
Step 3: For a norm, ‖ · ‖, and PSD matrix, Λ, define a policy class D, and select d0 ∈ D.
Step 4: For the policy di, find the balanced policy weights W ∗ and calculate ψ̂W ∗,Ŷ (di) according to
equation (4.11).
Step 5: Calculate the gradient of the policy, di, with respect to ψ̂W ∗,Ŷ (di) and use gradient
ascent/descent methods to find an improved policy di+1 ∈ D.
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Step 6: Repeat steps 4-5 until convergence to an estimated optimal policy d̂.
4.3 Simulation Studies
In this section we present the results of simulation studies to compare the small sample performance
of the proposed method with some existing alternatives. The methods that we use to compare are both
regression-based estimators as defined in equation (4.4). The first is a semiparametric approach based on
the Cox proportional hazards model (Cox, 1972). For the Cox model we must specify the relationship
between the covariates and the dose. Specifically, we assume that given X, the treatment dose and the
reward have a quadratic relationship. Thus the covariates used are (X,A,X2, XA,A2). The second
model is a nonparametric approach using recursively imputed survival trees (RIST) using the tuning
parameter values suggested in Zhu and Kosorok (2012).
For the balanced policy with imputation method we use the Mahalanobis RBF kernel from equation
(4.8) to define the worst case bias. The hyperparameters for this kernel are chosen by the marginal
likelihood method using Gaussian process regression. The conditional expected survival times, Ŷ , are
found based on the RIST model. We assume that the optimal policy comes from the logistic policy class
defined in equation (4.13). The optimization problem defined in (4.12) is non-convex. To find the
estimated optimal policy d̂, we use the l-BFGS algorithm (Fletcher, 2013) with random restarts.
To evaluate the performance of the approaches, a testing dataset with size 5000 is used to
approximate the average difference between the estimated and true optimal doses. For each setting the
methods are fit to datasets of size N = 250, 500, and 1000. Each simulation is repeated 100 times.
4.3.1 Simulation Settings
For each setting we draw a 10-dimensional covariate vectors X = (X1, . . . , X10)T , independently
from a standard normal distribution. The optimal dose is a linear function of the first two covariates with
dopt = 0.5 + 0.25X1 + 0.15X2. After drawing failure and censoring times, the maximum follow-up
time τ is set as the 98th percentile of the observed failure time distribution {Yi : ∆i = 1}.
In the first setting, the failure time is distributed according to the Weibull distribution with shape







for t ≥ 0. We let k = 2 and
λ = exp{1− 0.5X1 + 0.3X2 − 0.3X3 − 2(dopt −A)2}.
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The censoring times are distributed according to a log-normal distribution with parameters µ = 1 and
σ2 = 1. The censoring rate for this setting is approximately 35%. In this setting the Cox proportional
hazards model is correctly specified in terms of both the failure time distribution and the covariate
treatment relationship.
In the second setting, the failure time is distributed according to the log-normal distribution with
parameters
µ = 1 + 0.5X1 + 0.3X2 − 0.3X3 − 2 ∗ (dopt −A)2
and σ2 = 1. The censoring times are distributed according to a log-normal distribution with parameters
µ = 0 and σ2 = 1. The censoring rate for this setting is approximately 65%. For this setting the
covariate treatment relationship is correctly specified for the Cox proportional hazards model, but the
proportional hazards assumption is not met.
In the third setting, is identical to the second except that the failure time is distributed according to
the log-normal distribution with parameters
µ = 1 + 0.5X1 + 0.3X2 − 0.3X3 − 3 ∗ (dopt −A)3/2
and σ2 = 1. The censoring rate for this setting is approximately 55%. For this setting neither the
proportional hazards assumption nor the covariate treatment relationship are correctly specified for the
Cox proportional hazards model.
4.3.2 Simulation Results
The performance of the methods is measured by the average absolute difference between the
predicted and true optimal doses, as well as the average expected failure time under the estimated
policies. The average absolute difference results for all 3 simulation settings can be found in Figure 4.8,
while the average expected failure time can be found in Figure C.14 in Appendix C.
For setting 1, the Cox proportional hazards model is theoretically optimal, and we see that the
approach based on this model is outperforming the other approaches at all sample sizes. The balanced
policy with imputation approach has higher variance that the Cox-model based approach, but the median
performance of both methods is similar, especially for the smallest sample size.
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In setting 2, the balanced policy with imputation approach is performing better on average than the
other methods. Due to the high censoring rate and a low signal to noise ratio this setting, the balanced
policy and Cox-model based approaches have high variance. However, the variance reduces quickly as
the sample size increases.
For setting 3, the balanced policy with imputation approach is outperforming the other methods.
Settings 2 and 3 demonstrate that the Cox model based approach is sensitive to misspecification,
specifically in setting 3 where neither the proportional hazards assumption nor the covariate treatment
relationship are correctly specified. In contrast, the more flexible balanced policy approach allows it to
perform well in all three settings.
Due to the parametric piece of the Cox model and the parametric policy class used by the balanced
policy approach, it is possible for these methods to find estimated optimal policies that assign every
subject to the minimum or maximum doses. This generally happens when numerical instabilities cause
one or more parameters to become very large in absolute value. This can be seen in setting 2 for the
smallest sample size. The policies for the nonparametric regression based approach constrained to be
within the observed dose range, and tend to assign doses near the center of that range. Thus we do not
have this issue with the approach based on RIST.
4.4 Warfarin Case Study
Warfarin is a common anticoagulant agent used to prevent blood clots in patients at risk for
pulmonary embolism or stroke. Proper dosing of Warfarin is critical because too low of a dose leaves the
patient at risk for developing a thrombosis, while a dose that is too high can lead to internal bleeding.
The clotting tendency of a patient’s blood is measured using the international normalized ratio (INR). A
therapeutic dose of Warfarin is typically one that achieves a stable INR between 2 and 3. It is difficult to
establish the appropriate dose of Warfarin because it can vary by a factor of 10 between patients (The
International Warfarin Pharmacogenetics Consortium, 2009). Finding the appropriate dose of Warfarin is
generally done by trial and error by starting the patient at a initial dose and adjusting the dose in small
increments until a stable INR within the therapeutic range is achieved. The goal of this process is to find












































































































































































































































Figure 4.8: Boxplots showing the average absolute difference between the predicted and true optimal
doses. Smaller is better. Cox: Regression-based estimator using the Cox model, RIST: Regression-based
estimator using RIST, BP: Balanced policy evaluation with imputed survival time vector.
57
By defining the outcome to be the number of adjustments required to find the therapeutic dose, we
can formulate the outcome as time-to-event which may be subject to right censoring. If we assign the
initial dose according to a policy, we can use the methods described above to find an optimal policy that
minimizes the number of needed adjustments. The publicly available data on Warfarin dosing does not
contain information in the number of adjustments for each patient, so we instead consider a
semi-simulated scenario based on the available data.
The International Warfarin Pharmacogenetics Consortium (2009) provided a clinical algorithm for
estimating the optimal dose based on commonly available clinical measures. We use a slightly modified
version of this algorithm to determine the “true” therapeutic dose for each subject in the dataset based on
age, height, and weight information.
To simulate the number of adjustments, a dosing adjustment algorithm was designed to behave
similarly to the Warfarin Management Clinical Practice Guidelines published by the University of
Wisconsin health system (UWHealth, 2015). This guideline recommends adjusting the dosage in small
increments based on the INR value, with larger increments for INR values farther from the therapeutic
range. Since there is no way to reliably estimate the INR for every dose patient combination, we instead
based the adjustment increments on an error prone measure of the difference between the assigned and
optimal dose.
The initial dose values, Ai, are drawn from a truncated normal distribution on the interval [0,1], with
mean µ = dopt(Xi) + εi where εi ∼ unif(−0.15, 0.15) and standard deviation σ = 0.3. The censoring
times were drawn from a discreet distributing with support over the observed range of the failure times,
{1, . . . , 11}. The censoring rate was approximately 30%. Full details on each of these components can
be found in Appendix C.
After removing subjects which had missing values, the data consisted of 1784 subjects with
information on 7 clinical and demographic measures. Specifically, the covaraites were age in decades,
weight (kg), height (cm), Gender (M/F), Race (white/black/asian), and two indicators for medications:
Enzyme(Y/N) and Amiodarone (Y/N). We randomly split the data into training and testing datasets of
equal size 100 times. We compared the Cox model and RIST regression-based approaches, as well as
balanced policy with imputation. The performances of different methods are evaluated by comparing the
average difference between the predicted and true doses across the 100 splits. The results can be found in
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Figure 4.9. The results show that the balanced policy with imputation approach was better able to
























Figure 4.9: Boxplot showing the average absolute difference between the predicted and true optimal
doses for the Warfarin example. Smaller is better. Cox: Regression-based estimator using the Cox model,
RIST: Regression-based estimator using RIST, BP: Balanced policy evaluation with imputed survival
time vector..
4.5 Discussion
The balanced policy with imputation approach is effective at finding good dosing policies when
compared to regression-based methods for right-censored data. By using the balanced policy weights and
a regression-based imputation approach to right censoring, we were able to avoid many of the
high-variance issues experienced by other weight-based approaches. This allowed the proposed approach
to achieve good performance even with small sample sizes. The imputation approach can be used to
extend other dose finding methods to right censored data, including the methods proposed by Kallus and
Zhou (2018) and Chen et al. (2016). It would be of great interest to compare the performance of
balanced policy evaluation with imputation with similar extensions of these methods.
There are a number of ways in which the proposed method may be improved or extended. It is
possible to define a doubly robust version of the balanced policy estimator. A doubly robust estimator
that combined the efficiency of the Cox model with the relaxed assumptions of balanced policy
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evaluation could achieve good performance in a large number of scenarios. However, deriving a learning
algorithm to find the optimal policy for the doubly robust estimator is beyond the scope of this project.
The proposed method is more computationally intensive than existing approaches, and thus it is limited
to comparatively small datasets. More efficient optimization procedures, such as alternating descent or
boosting with a faster approximate method, could allow the proposed method to be applied to larger
datasets.
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CHAPTER 5: POSSIBLE APPLICATIONS TO ENVIRONMENTAL HEALTH AND ASTHMA
5.1 Environmental Health and Asthma
Environmental health is a subdiscipline of public health which studies the impact that environmental
factors have on human health. These environmental factors can come from either the natural, or the built
environment. The world health organization (WHO) website on environmental health states:
Environmental health addresses all the physical, chemical, and biological factors external to
a person, and all the related factors impacting behaviours. It encompasses the assessment
and control of those environmental factors that can potentially affect health. It is targeted
towards preventing disease and creating health-supportive environments. This definition
excludes behaviour not related to environment, as well as behaviour related to the social and
cultural environment, and genetics (World Health Organization, 2019b).
By creating and maintaining healthy environments, environmental health seeks to increase the quality of
life and the years of healthy life for all members of a population.
One of the main goals of environmental health efforts is to improve the air quality. This applies to
both outdoor environments as well as indoor environments where a large proportion of the population
spend the majority of their time (Klepeis et al., 2001). Air quality has been identified as a significant risk
factor for a number of diseases including acute lower respiratory infections, ischaemic heart disease,
chronic obstructive pulmonary disease, stroke, lung cancer, and asthma (World Health Organization,
2014; Beasley et al., 2015).
Asthma is a long-term inflammatory condition often characterized by a rapid onset of airway
constriction and bronchospasms (Kay, 1991). The symptoms of asthma can vary between individuals but
generally include coughing, wheezing, a shortness of breath, and tightness in the chest. There is also a
wide range in both the frequency and severity of symptoms experienced by patients, occurring anywhere
from a few times per week to multiple times per day, and ranging from relatively mild to life threatening
(Reddel et al., 2017). The WHO estimates that 235 million people currently suffer from asthma (World
Health Organization, 2019a). The mortality of asthma is lower than for other chronic conditions, but it
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was estimated in 2016 that approximately 250,000 people die prematurely from asthma related
symptoms each year (D’Amato et al., 2016).
The cause of asthma is unclear, but many risk factors have been identified including exposure to
smoking, air pollution, animal dander, dust mites, and mold (Beasley et al., 2015). One of the major
components of air pollution that affects asthma is ozone (White et al., 1994). There is also a documented
connection between asthma symptoms and allergic rhinitis which can be caused by any number of
allergens (Simons, 1999). Therefore, many of the factors that influence the development of asthma and
the management of the symptoms are environmental in nature.
The severity of asthma is categorized by the frequency with which the patients experience symptoms
(Yawn, 2008). Because of this, many useful measures of the effectiveness of treatments relate to a
decrease in the rate of symptomatic episodes. This naturally lends itself to be analyzed using
time-to-event outcomes. For example, time until next onset of symptoms or time until next
hospitalization. These time-to-event outcomes would likely be subject to right censoring, and thus we
could apply the methods discussed in chapters 2-4.
5.2 Balanced Policy Learning for the Treatment of Asthma
Medication is one of the many treatment types available for asthma, of which there are two main
types. Fast-acting medications for immediate relief of symptoms, and long-term-control to prevent
symptoms from occurring. Among the long-term-control medications, there are three general classes of
medications, corticosteroids, long-acting β-adrenoceptor agonists, and leukotriene receptor antagonists.
Corticosteroids are the standard treatment course, but drugs from other classes may be prescribed alone
or in combination therapies if needed. Currently, the decision to switch to an alternative therapy is made
after the patient fails to respond to corticosteroids alone or because of a adverse reaction (Mannino,
2017).
By using the method proposed in Chapter 3, we may be able to identify certain subpopulations that
would respond more favorably to a non-standard treatment course. In this setting we would need to
include several measures of environmental exposures in the covariate vector X . The environmental
factors are unlikely to be tailoring variables because they would have no direct effect on the treatment
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response. However, they would still need to be included to satisfy assumption 3.1 since the outcome of
interest would most likely depend on these factors.
5.3 Balanced Policy Evaluation for Allergen Exposure
Both asthma and allergic rhinitis affect inflammation in the airways and there is a recognized clinical
association between the two conditions. It is unclear to what extent the conditions are related, but the
natural histories are similar, as are some of the seasonal exacerbations. Epidemiologic studies have
confirmed that asthmatic patients with severe allergic rhinitis tend to have worse symptoms than those
with mild allergic rhinitis (Simons, 1999).
It may be of interest to understand the degree to which exposure to allergens increases the rate of
severe asthma symptoms. By treating the exposure to environmental allergens as a continuous dose, we
could use the method proposed in chapter 4 to answer this question. The exposure to allergens is most
likely not a modifiable risk factor, and thus policy learning is not applicable. However, we could still use
policy evaluation to better understand how an increased pollen count may affect the incidence of severe
asthma symptoms.
5.4 Balanced Policy Learning for Ozone Exposure
Ozone can be produced by any machinery that produces electrical discharges (Kogelschatz et al.,
1988). A large amount of ozone can be generated by devices that use high voltages, such as air purifiers,
laser printers, photocopiers, and motors that use brushes. This can lead to substantial ozone exposure in
indoor environments. Exposure to ozone has been linked to increased frequency and severity of asthma
attacks (White et al., 1994).
Since ozone is a pollutant, reducing the exposure is likely to be associated with better health
outcomes. However, given the large number of common machines and appliances that produce ozone, it
is reasonable to assume that any reduction in exposure will come at significant cost. If the cost of
implementing a policy can be calculated, we could use a modified version of the method proposed in
Chapter 4 to find the optimal policy that accounts for both cost and health outcomes. Let C(d) be the
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+ λC(d) : d ∈ D,W ∈ argmin
W∈W
E2(W,d; ‖ · ‖,Λ)
}
,
where λ is chosen to make the cost and health outcomes comparable. This optimization would be
straightforward for simple policy classes, such as having the same exposure for everyone, or reducing the
observed exposure by some multiplicative factor.
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CHAPTER 6: DISCUSSION AND FUTURE RESEARCH
Precision medicine is an increasingly important aspect of healthcare, and has the potential to greatly
improve the lives of patients. Time-to-event data is common in medical applications, but many precision
medicine methods do not work in the presence of right censoring. In this dissertation, we have presented
several extensions of precision medicine methods to right censored data. Chapter 2 discussed a novel
approach to predicting failure times in a way that makes full use of the available data. The theoretical
properties of the method have been investigated. We demonstrated that it performed better than similar
existing approaches, especially when the rate of censoring is high. In Chapter 3 we introduced an ITR
estimation method for right censored observational data when multiple treatment options are available.
By using balanced policy evaluation and learning in conjunction with an imputation approach to correct
for censoring, the method is able to achieve good performance without relying on the restrictive
assumptions of some regression-based methods. We examined the theoretical properties of the proposed
method and demonstrated that it performs better than existing alternatives. The balanced policy method
for right censored data was extended to the continuous treatment setting in chapter 4. We demonstrated
that this approach performs well in comparison to regression based estimators.
The method in Chapter 2 could be extended by including the comparable pairs described in
(Van Belle et al., 2011). The difficulty in this approach is constructing a loss function capable of
correcting for the bias due to censoring. Including all of the comparable pairs is not computationally
feasible because the number of comparable pairs can grow at a rate on the order of n2. This necessitates
a method of choosing which comparable pairs will be included in the objective function. Van Belle et al.
(2011) chose to use adjacent comparable pairs (i.e. comparing the ith data point with the comparable
neighbor with the largest failure time smaller than Yi). Correcting for the probability of observation for
adjacent comparable pairs would require weights based on the distribution of the order statistics of the
observed times, which would depend on the distributions of the survival and censoring times. It is
possible to choose a subset of the comparable pairs in a manner that makes the correcting weights easier
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to estimate, but non-adjacent comparable pairs likely do not contain as much information as adjacent
pairs.
The methods discussed in Chapters 3 and 4 are concerned with ITR estimation in the single decision
setting. In chronic diseases, it is often necessary to make many treatment decisions over the course of the
patients life. The ITR estimation problem is much more difficult in the multi-decision setting because we
must account for not only the immediate, but also the long term effects of the treatment. For example,
assigning a patient to an aggressive course of treatment may lead to worse clinical outcomes initially, but
lead to much better outcomes in the long term. In Kallus (2019) the author describes how balanced
policy evaluation and learning can be extended to the multi-decision setting. It may be possible to extend
our balanced policy method for right censored data in a similar manner.
In Chapter 4 we discussed the potential for a doubly robust version of the balanced policy estimator.
As the method is currently defined, a doubly robust version of policy evaluation is a very straightforward
extension. However, developing a optimization approach for balanced policy learning needs further
refinement. The task is most likely not too difficult when using parametric or semiparametric models for
the regression-based component of the doubly robust estimator, but is much more difficult for
nonparametric models. In the simulation studies of Chapter 4, the regression-based approach using the
Cox model performed surprisingly well, even when the proportional hazards assumption was not met. A
doubly robust version of the estimator could be used to exploit the efficiency of the Cox model, while
using the balanced policy weights to correct for minor misspecification issues.
The methods presented in Chapters 3 and 4 require considerable computational power. This
currently limits their use to comparatively small datasets. The largest issue is that the methods require a
bilevel optimization procedure, where a quadratic optimization problem must be solved at each step of
the gradient ascent algorithm. An alternating descent algorithm may be able to improve the
computational efficiency of these methods. Alternatively, it may also be advantageous to boost the
balanced policy approach in Chapter 3 using a more faster approximate method.
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APPENDIX A: ADDITIONAL DETAILS FOR CHAPTER 2
Derivation of the dual form























′φ(Xi) + b− Yi + ε+ ξi) ≥ 0 ∀ i = 1, . . . , n
∆i(Yi − β′φ(Xi)− b+ ε+ ξ∗i ) ≥ 0 ∀ i = 1, . . . , n
(1−∆i)(β′φ(Xi) + b− Yi + ε+ χi) ≥ 0 ∀ i = 1, . . . , n
ξi ≥ 0, ξ∗i ≥ 0, χi ≥ 0 ∀ i = 1, . . . , n.
We can write the Lagrangian of the primal form as,




















αi∆i{β′φ(Xi) + b− Yi + ε+ ξi} −
n∑
i=1











































− α∗i − µ∗i .
Setting the derivatives to zero an solving, we can replace β, ξ, ξ∗, and χi in the dual form:












αi∆i(Yi − ε) +
n∑
i=1






0 ≤ αi, α∗i ≤
κ∆i
Ŝc(Yi|Xi)





First, since Y and f(X) are both restricted to between 0 and τ , it is clear that there exist constants c1
and c2 such that
LT (Y, f(X)) ≤ B ≡ max(2τ, 2τ2),
∣∣∣LT (Y, z)− LT (Y, 0)∣∣∣ ≤ c1|z|+ c2z2
for z ∈ [0, τ ].
To prove Theorem 1, we fist prove the following lemma.
Lemma 2. Let LC(Y,∆, f(X)) be the loss function defined in (2.1). Fix constants λ > 0, η > 0, and
let f ∈ H. Then for all n ≥ 72η,
(P − Pn)
[





















where, r∗ = inff∈H λ‖f‖2H + P
[
LC(Y,∆, f̂λ(X))− LC(Y,∆, f∗(X))
]
, and W > 1 is a constant that
depends only on V defined in 2.1, and B is an upper bound for LC , and p defined in 2.3, but not on f .
Proof. Note that if q2p > λpn then the inequality holds trivially with W ≥ 2BV . Therefore, we restrict
our attention to the case where q2p ≤ λpn. For every function f ∈ H, define,
hf ≡ hf (Y,∆, x) = LC(Y,∆, f(X))− LC(Y,∆, f∗(X)).
For all x, y ∈ X × Y define,
gf,r ≡
Phf − hf
λ‖f‖2H + Phf + r
, f ∈ H, r > r∗.
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By assumptions 2.1-2.2, we have that for every f ∈ H, ‖gf,r‖∞ ≤ BV r . Steinwart and Christmann (2008)
equation 7.43 shows that Pg2f,r <
B


























holds with probability greater than or equal to 1− e−η for every fixed γ > 0.
Using assumption 2.3 together with Steinwart & Christmann Theorems 7.20 and 7.23, it can be









































holds with probability no less than 1− e−η. Following the arguments and algebraic manipulations of























holds with probability no less than 1− e−η.





+ 72ηB2V n + r
∗ to obtain the inequality,
(P − Pn)
[











holds with probability not less than 1− e−η.
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Proof of Theorem 1: Define the empirical risk with respect to a loss function L for a given decision
function f as




The corresponding expectation is denoted asRL,P (f).
By the definition of fλ,




λ‖f̂λ‖2H +RLT ,P (f̂λ)−R
∗
LT ,P
≤ λ‖f0‖2H +RLĈ ,n(f0)−RLĈ ,n(f̂λ) +RLT ,P (f̂λ)−R
∗
LT ,P
= λ‖f0‖2H +RLT ,P (f0)−R
∗
LT ,P (A.4)
+RLĈ ,n(f0)−RLC ,n(f0) (A.5)
+RLC ,n(f0)−RLT ,P (f0) +RLT ,P (f̂λ)−RLC ,n(f̂λ) (A.6)
+RLC ,n(f̂λ)−RLĈ ,n(f̂λ). (A.7)
Next we examine each line of (A.4)-(A.7). From Section 2.1,
RLT ,P (f) =E (LC(y, f(x))) = RLC ,P (f).
Thus, for every function f ∈ H, if we define
hf ≡ hf (Y,∆, X) = LC(Y,∆, f(X))− LC(Y,∆, f∗(X)),
then (A.4) is equivalent to λ‖f0‖2H + Phf0 . For (A.5), since by assumption,
‖LC(Y,∆, f0(X))‖∞ ≤ B02V and ‖LĈ,n(Y,∆, f0(X))‖∞ ≤
B0
V , it holds










− ∆|y − f0(X)|
Sc(y|x)









(∣∣∣(Sc − Ŝc) (Y |X)∣∣∣+ ∣∣∣(gc − ĝc)(Y |X)∣∣∣) . (A.8)
On the other hand, we can rewrite line (A.6) as
RLC ,n(f0)−RLT ,P (f0) +RLT ,P (f̂λ)−RLC ,n(f̂λ)
= (Pn − P ) (hf0 − hf̂λ).
Since, for any f ∈ H and given that assumption 2.1,





(|Y − f(X)| − |Y − f∗(X)|) + (1−∆)
gc(y|x)






(|Y − f(X)| − |Y − f∗(X)|)2 + (1−∆)
g2c (y|x)








(|Y − f(X)| − |Y − f∗(X)|) + (1−∆)
gc(y|x)





P [LC(Y,∆, f(X))− LC(Y,∆, f∗(X))] ,
noting that the definition of LC and assumptions 2.1-2.2 imply LC(Y,∆, s) ≤ B2V , it follows directly
from Steinwart & Christmann Theorem 7.2 equation 7.8, for all n ≥ 8η, that






holds with probability not less than 1− e−η. Additionally, by Lemma 2 with probability not less than
1− e−η, for all n > 72η,
















Finally, by an argument similar to equation (A.8) we obtain




(∣∣∣(Sc − Ŝc) (Y |X)∣∣∣+ ∣∣∣(gc − ĝc)(Y |X)∣∣∣) , (A.10)
which provides a bound for line (A.7).
Consequently, Therefore, we conclude from (A.8), (A.9), and (A.10) that for all n ≥ 72η,
λ‖f̂λ‖2H +RLT ,P (f̂λ)−R
∗
LT ,P




















SinceRLT ,P (f̂λ)−R∗LT ,P = Phf̂λ and B0 ≥ B, this yields that























holds with probability not less than 1− 3e−η.
Until now it was assumed that n ≥ 72η. Now assume that n < 72η. Since
λ‖fλ‖2H +RLT ,P (f̂λ)−R
∗
LT ,P




(∣∣∣(Sc − Ŝc) (Y |X)∣∣∣+ ∣∣∣(gc − ĝc)(Y |X)∣∣∣)

















since 72ηn > 1 and B0 ≥ B. Therefore,



















We have proved theorem.


















for any fixed constant λ > 0, n ≥ 1, and η > 0 with probability not less than 1− 3e−η.
We first prove the universal consistency. Define B0 = B + c3(A2(λ)/λ)1/2 + c4(A2(λ)/λ) for
c3 = c1(supx∈X
√
K(x, x))1/2 and c4 = c2(supx∈X
√
K(x, x)). Since the kernel K is bounded, it
follows from Steinwart and Christmann Lemma 4.23 that ‖fP,λ‖∞ ≤ supx∈X
√
K(x, x)‖fP,λ‖H. By
the definition of A2(λ), ‖fP,λ‖H ≤ (A2(λ)/λ)1/2. For all (x, y) ∈ X × Y ,
LT (Y, fP,λ(X)) ≤ LT (Y, 0) + |LT (Y, fP,λ(X))− LT (Y, 0)| ≤ B + c1|fP,λ(X)|+ c2fP,λ(X)2.
Thus,
‖LT (Y, fP,λ)‖∞ ≤ B + c1‖fP,λ(X)‖∞ + c2‖fP,λ(X)‖2∞














≤ B + c3(A2(λ)/λ)1/2 + c4(A2(λ)/λ) = B0.
By letting λ = λn, it follows from Assumption 2.4 and Steinwart & Christmann Lemma 5.15 that













(∣∣∣(Ŝ − Sc) (Y |X)∣∣∣+ |(ĝ − gc) (Y |X)|)





→ 0 because λpnn→∞ as n→∞. Thus, for
every fixed η > 0, we have obtained
λ‖fλ‖2H + P
[
LT (x, Y, f̂λ)− LT (x, Y, f∗)
]
→ 0
in probability for every distribution P .
To establish learning rates, first, from assumption 2.5, there exists constants b1 and b2 that depend
only on η, such that for all n ≥ 1,
P



















s and ‖(ĝc − gc) (Y |X)‖∞ ≥ b2n
− 1








. Recall that B0 = B + c3(A2(λ)/λ)1/2 + c4(A2(λ)/λ) and the assumption 2.6,































where b4 = 3 max{b3, 144ηV ,
1
3}, c5 = max{B,
√
c0c3, c0c4} and, s̃ = min{1, 1s ,
1
s′ }. Using this bound




















Now let λ = n−
ρ















where c6 = max{8c0, 2Wq2p, c5}. Note that ψs̃+(ψ−1)ρψ ≥
2ψs̃+(ψ−1)ρ








, it follows that
λ‖fλ‖2H+RLT ,P (f̂λ)−R
∗
LT ,P = Op(n
−ρ).
We obtain the result.
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APPENDIX B: ADDITIONAL DETAILS FOR CHAPTER 3
Proofs:






















we can bound each term separately. Focusing on the rate at which Ŷ → Ỹ , consider the form of Ŷ
∫ τ











The first quantity depends on the pair (Ŝ(t |X,A), Ŝ(Y |X,A)) through the two maps




















y t dS(Y |X,A)β(y)
S2(y |X,A)
.
Similarly, the second quantity depends on the pair (Ŝ(t |X,A), Ŝ(Y |X,A)) through the two maps


















By the Hadamard differentiability of the maps, Theorems 2.8 and 12.1 of Kosorok (2008), and
Assumption 3.2 we have that 1n
∑n































The proof of (Kallus, 2017) Theorem 3 implies that 1n‖W‖
2



















































(1−∆i)(Ên−1(T |Xn, An, T > Yn)− E(T |Xn, An, T > Yn))2
]
≤ τE
[∣∣∣Ên−1(T |Xn, An, T > Yn)− E(T |Xn, An, T > Yn)∣∣∣ ∧ τ]
(since both Ên−1[T ] and E[T ] are constrained to be ∈ (0, τ ])
= τE













[∣∣∣∣∣−2τ Ŝn−1(τ |X,A) + Y Ŝn−1(Y |X,A) +
∫ τ




2τS(τ |X,A)− Y S(Y |X,A)−
∫ τ
Y S(t |X,A) dt
S(Y |X,A)
∣∣∣∣ ∧ τ] .
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By adding and subtracting
2τS(τ |X,A)− Y S(Y |X,A)−
∫ τ
Y S(t |X,A) dt
Ŝn−1(Y |X,A)
,



















If we assume that
inf
X,A















































Ŝn−1(t |X,A)− S(t |X,A)
)∣∣∣∣ .




i=1(1−∆i)Wi(Ỹi − Ti). Let Fi = σ(Xi, Ai, Yi,∆i) be the sigma field for a single observation
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and Fn = σ(
⋃
1≤i≤n
Fi). For any i, note that
E[(1−∆i)Wi(Ỹi − Ti)] = E
[




(1−∆i)WiE[(Ỹi − Ti) |Fn]
]
= E [(1−∆i)Wi (E[Ti |Xi, Ai, Yi]− E[Ti |Xi, Ai, Yi])] = 0.
For 1 ≤ i 6= j ≤ n, also note that
E[(1−∆i)Wi(Ỹi − Ti)(1−∆j)Wj(Ỹj − Tj)]
= E
[








E[(Ỹi − Ti)(Ỹj − Tj) |σ(Fi ∪ Fj)]
= E
[
E[(Ỹi − Ti) |Xi, Ai, Yi,∆i]E[(Ỹj − Tj) |Xj , Aj , Yj ,∆j ]
]
= 0.
This implies that 1n
∑n

















(1−∆i)W 2i (Ỹ − T )2
]
→ 0,






(1−∆i)Wi(Ŷi − Ti) = Op(rn).
Additional Simulation Study Results
Figure B.10 shows the results for simulation setting 1 for the simple weighted and doubly robust
estimators. For this setting, the mean was a complicated function of the covariates. The nonparametric
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Figure B.10: Boxplots showing estimated population regret for setting 1. Smaller is better. IPW+IPCW:
IPW combined with IPCW; IPCW+Ŷ : IPW with imputed outcome vector; BP+Ŷ : Balanced policy with
imputed outcome vector. Doubly robust versions used the correctly specified AFT model for µ̂.
Figure B.11 shows the results for simulation setting 2 with and without variable selection. For the
smaller sample sizes, the variable selection method used was unable to reliably identify the meaningful
variables. For the largest sample size, variable selection was able to improve the performance of the
policy learners, which is most clearly seen in the IPW+Ŷ and IPW+IPCW estimators.
Additional Application Study Results
The differences between the different INSTIs during the first 2.5 years of followup were quite small.
A larger difference between RAL and EVG does not start to appear in the Kaplan-Meier plots until about
3 years of follow-up, indicating that there may be some effects that do not manifest until later in the
treatment course.
Based on clinical experience, we believe that treatment naı̈ve patients should respond differently
than treatment experienced patients and younger patients should respond differently than older patients.
Figure B.12 shows survival curves broken down by treatment and treatment experience, and by




































































































































































Figure B.11: Boxplots showing estimated population regret for setting 2. Smaller is better. IPW+IPCW:
IPW combined with IPCW; IPCW+Ŷ : IPW with imputed outcome vector; BP+Ŷ : Balanced policy with
imputed outcome vector. Doubly robust versions used the correctly specified AFT model for µ̂.
associated with longer survival times. Similarly, for patients aged 30 years and younger as well as
patients over 30, Dolutegravir appears to be superior to the other treatment options.












































Figure B.12: The left plot shows the survival curves for each treatment broken down by treatment naı̈ve
vs. experienced. The right plot shows the survival curves for each treatment broken down by age≤30 vs
age> 30. In both cases Dolutegravir was associated with longer survival times in each subpopulation.
Figure B.13 shows the average projected survival curves under several ITR estimation methods, as
well as the observed survival curve for the modified data. The regression based method resulted in a
projected survival rate which is less than the observed survival rate in the data. The other methods
examined resulted in improved projected survival rates when compared to the observed rate, but the best
projected survival rates were associated with balanced policy evaluation with imputation.
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Figure B.13: Average projected survival curves under several ITR estimation approaches compared to
the observed survival curve. Reg: Regression-based approach; IPW+IPCW: IPW combined with IPCW;
IPCW+Ŷ : IPW with imputed outcome vector; BP+Ŷ : Balanced policy with imputed outcome vector.
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APPENDIX C: ADDITIONAL DETAILS FOR CHAPTER 4
Warfarin Simulation Details
The optimal dose is calculated from the observed covariates according to the formula:
optimal_dose = (0.43− 0.06× Age + 0.04× Weight + 0.07× Height),
where the overline indicates the centred and scaled covariate values.
The assigned treatments are randomly drawn for each subject such that:
trt ∼ Truncated Normal(min=0, max=1, mean = optimal dose+ε, sd = .3),
where ε ∼ Unif(−0.15, 0.15))
The time until stable dosing of Warfarin are simulated according to Algorithm C.1.
Algorithm C.1. Pseudo-algorithm for simulating time until stable dose in Warfarin study.
Step 1: Let time=0, new_trt=trt, and
target_dose=optimal_dose + ε where ε ∼ Unif(−0.15, 0.15)).
Step 2: If |target_dose− trt_temp| < 0.025 go to step 6, else go to step 3.
Step 3: Set time=time+1, and let diff = |target_dose− trt_temp|,
Step 4: draw dose_change according to the following:
0.025 ≤ diff < 0.1 dose_change ∼ Unif(0.0, 0.05),
0.1 ≤ diff < 0.2 dose_change ∼ Unif(0.05, 0.1),
0.2 ≤ diff dose_change ∼ Unif(0.1, 0.15).
Step 5: Return to step 2.
Step 6: Set the stable dose time T = time.
The censoring times were drawn from a discrete uniform distribution over {1, . . . , 11} with probabilities
{0.1, 0.15, 0.15, 0.2, 0.2, 0.05, 0.05, 0.05, 0.025, 0.025}.








































































































































































































































































































Figure C.14: Boxplots showing the average expected failure time under the estimated policies. Larger is
better. Cox: Regression-based estimator using the Cox model, RIST: Regression-based estimator using
RIST, BP: Balanced policy evaluation with imputed survival time vector.
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